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Background/Objectives: Low areal bone mineral density (aBMD) of the hip and knee region 
has been associated with fracture risk in individuals with SCI; however the contribution of 
bone micro-architecture to fracture risk has not been evaluated. The primary objective of this 
study was to determine whether a relationship exists between indices of bone strength (aBMD 
at the distal femur and proximal tibia; trabecular vBMD; average hole size, HA; cortical 
thickness, CTh; buckling ratio, BR; cross-sectional moment of inertia, CSMI; and polar 
moment of inertia, PMI) and potential fracture risk factors (gender, age, bisphosphonate use, 
time post-injury, fractures, and completeness of injury). The secondary objectives were to 1) 
determine whether indices of bone strength can discriminate between SCI patients with and 
without fragility fractures; 2) determine if these indices of bone strength correlate with the 
number of fractures sustained; and 3) determine the proportion of individuals with SCI who 
have a trabecular vBMD at the ultra-distal tibia that is below 72mg/cm
3
.  
Materials and Methods:  A nested case-control study was performed. Forty seven men 
(n=33) and women (n=14) with chronic SCI (C2-T12 AIS A-D) with a duration of paralysis 
of at least two years were included in this study. Subjects with SCI were questioned about the 
cause, location, and time of the lower extremity fragility fractures. Fracture presence was 
verified by x-rays. aBMD of the distal femur and proximal tibia were determined using dual 
energy x-ray absorptiometry (DXA).  Trabecular volumetric bone mineral density (vBMD) 
and HA were measured at 4% of the tibia length, and CTh, BR, CSMI, and PMI were 
measured at 66% of the tibia length of individuals with chronic SCI using peripheral 
quantitative computed tomography (pQCT). Linear and multiple regression models were used 
to determine significant correlates (age, gender, completeness of injury, duration of injury, 
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bisphosphonate use, and fractures) of indices of bone strength, while logistic regression was 
used to assess the relationship between indices of bone strength and fragility fractures. To 
assess the relationship between multiple fragility fractures and indices of bone strength, a 
poisson regression analysis was performed. 
Results: Risk factors found to be related to the indices of bone strength include gender, 
completeness of injury, duration of injury, bisphosponate use, and prior fractures. An increase 
in HA (OR=1.081, 95% CI=1.001-1.166, p=0.0470), a decrease in aBMD in the distal femur 
(OR=0.988, 95% CI=0.978-0.998, p=0.0226), and a decrease in CSMI (OR=0.098, 95% 
CI=0.012-0.838), p=0.0338) were associated with fractures. Fractures were not associated 
with aBMD at the proximal tibia, trabecular vBMD, CTh, or BR. The poisson regression 
model predicting the number of fragility fractures sustained among individuals with chronic 
SCI from aBMD, vBMD, HA, CTh, CSMI, PMI, and BR were each statistically significant. 
Finally, only 7.7% of our population had a trabecular vBMD fracture threshold of less than or 
equal to 72mg/cm
3





 at the ultra distal tibia in individuals with complete and 
incomplete SCI, respectively. 
Conclusion: Specific bone strength measures, specifically aBMD at the distal femur, HA, and 
CSMI are associated with fracture risk and may improve our ability to identify individuals 
with SCI at high risk of fracture. Larger population based studies are needed to determine the 
most appropriate risk factors that contribute to bone loss and understand the role and 
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Individuals with a spinal cord injury (SCI) experience substantial declines in bone mass 
in the lower extremities [1-6], thereby increasing the risk of fragility fractures. Individuals 
with SCI are susceptible to low-energy fractures known as fragility fractures. Fragility 
fractures have been reported to most commonly occur among individuals with SCI during 
normal daily activities such as transferring from a chair to a bed, rolling in bed, or bumping 
into unseen objects [7-12]. The majority of fragility fractures in individuals with SCI occur 
around the knee at the distal femur and proximal tibia [1,6-8,11-13]. An individual with SCI 
has approximately twice the risk of suffering from a lower extremity fracture for each unit 
decline in hip and femoral neck t-score than age and gender matched individuals without SCI 
in their lifetime [7]. Fracture prevalence rates among individuals with SCI are reported to 
range from 1% to 34% [7-9,12,14]. Fragility fractures result in increased healthcare costs, 
long term hospitalization, and increased disability [14]; consequently, quality of life is 
reduced. Therefore, establishing strategies to improve the identification of individuals at high 
risk of fracture would facilitate fracture prevention/reduction strategies. 
Currently, areal bone mineral density (aBMD) assessed by dual-energy x-ray 
absorptiometry (DXA) is the gold standard for diagnosing osteoporosis and fracture risk in 
postmenopausal women and men over the age of 50 [15,16]. However, it is becoming 
increasingly apparent that aBMD alone is insufficient to predict fracture risk. New Canadian 
osteoporosis guidelines have proposed that clinical risk factors such as age, sex, prior fragility 
fractures, and glucocorticoid use be incorporated with aBMD to assess fracture risk [15,17]. 
Bone properties such as a bone’s structure and architecture also play a role in bone strength, 
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thus contributing to fragility fractures. Peripheral quantitative computed tomography (pQCT) 
is a new non-invasive technique that provides a measurement of volumetric bone mineral 
density (vBMD).  pQCT can also characterize a bone’s geometry, and  generate an index of 
bone strength that reflects the ability of bone to resist torsion or bending [18]. A few previous 
investigations of bone health among individuals with SCI have been performed using pQCT; 
in addition most of these studies were conducted in males. They report a decrease in total 
aBMD, trabecular vBMD, cortical thickness, and stress strain index by 45-47% [4,19], 15-
49% [19,20], 17-47% [4,19],17-19% [4], respectively, in the tibia compared to controls. 
Although SCI is uncommon in women, with a male-to-female ratio of approximately four to 
one [21], women in general are at high-risk of osteoporosis [17]. Therefore, we need to 
determine if women with SCI face greater deterioration of bone mass than men with SCI. 
pQCT has previously been used to determine bone structure in other fracture-prone 
populations such as post-menopausal women, dialysis patients, and children with cerebral 
palsy. Cortical and trabecular micro-architecture have been found to be strong correlates of 
bone strength and fracture risk in in vivo and in ex vivo studies [22,23]. For example, cortical 
thickness defined as the difference between the outer and inner radius of cortical bone, 
provides an index of the degree of endosteal resorption, and, in addition to cortical density 
and area, has been associated with fractures among individuals on dialysis [24]. Thinning of 
cortical bone leads to a distinct increase in the buckling ratio [25] among dialysis patients. 
Buckling ratio expresses the likelihood that bone will fail due to extreme cortical thinning. 
Another cross-sectional study demonstrated that the mean values for intertrabecular spacing 
within the bone marrow at the radius can distinguish between women with and without 
fractures [26]. Sornay-Rendu et al [27] reported that vBMD and changes in cortical and 
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trabecular structure are associated with fractures in postmenopausal women. In children with 
cerebral palsy (CP), stress-strain index of bone, a surrogate measure of bending strength that 
takes into account material properties of bone, was reduced by approximately 64% compared 
to healthy controls as a result of smaller and thinner cortical bone, and not because of a 
reduction in cortical bone density [28]. These studies confirm the importance of bone 
geometry, in addition to BMD, as indicators of bone strength. Review of lower extremity 
pQCT data may enhance our ability to predict fractures among people with SCI and low bone 
mass.  
Fracture threshold and fracture breaking point have recently been proposed in 
predicting fracture risk among individuals with SCI. Fracture threshold is defined as aBMD 
value in a specific skeletal site, below which osteoporotic-related fracture begin to occur, 
whereas fracture breaking point is defined as a point in which the majority of fractures occur 
[29]. Low BMD of the distal femur and proximal tibia has been found to be different among 
individuals with SCI with and without a history of fragility fracture. A study conducted by 
Garland et al [29] reported a DXA-based aBMD fracture threshold of 0.78mg/cm
2
 at the knee 
and a fracture breaking point of 0.49mg/cm
2
 in males with SCI. Recently, fracture threshold 
for vBMD were identified with a femoral distal epiphysis trabecular vBMD of less than 
114mg/cm
3
 and a tibia epiphysis trabecular vBMD of less than 72mg/cm
3
 among individuals 
with complete SCI [30]. Fracture threshold values may be a useful technique in assessing 
fracture risk among the SCI population, but further validation of its positive predictive value 
is required. 
 Despite the high rates of fracture occurrence, there are no consensus-based guidelines 
for the determination of fracture risk and optimal treatment for individuals with SCI, which 
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has resulted in variation of diagnostic protocols between SCI clinicians [31]. However, a 
protocol has been proposed in which fracture risk can be ascertained with aBMD 
measurements of the knee region and fracture risk factors [32]. The current practice of using 
DXA-based aBMD to predict fractures in men and women over the age 50 years cannot be 
applied to predict fracture risk in individuals with SCI because different risk factors apply 
[30]. Studies need to explore potential correlates associated with fractures among individuals 
with SCI to determine those at high risk of fracturing. Newer technology such as the pQCT 
allow for the analysis of bone structure and indices of bone strength. The current pQCT 
literature has small sample sizes, and focuses on men with motor complete paraplegia. Little 
is known about the changes in bone architecture that occur in females, tetraplegics, and 
individuals with an incomplete SCI. Therefore, characterizing changes in bone structure in a 
broad spectrum of individuals with SCI will improve our understanding about the 
physiological changes that occur in bone post-injury and will enhance our ability to assess 
fracture risk among individuals with different levels of neurological impairments. Fracture 
threshold values established by the pQCT may also be a useful diagnostic technique in 
fracture risk assessment; however there is no evidence that applies the vBMD fracture 
thresholds among individuals with SCI.  
In conclusion, this study will determine potential correlates of fracture risk, increase 
our understanding of fractures and bone structure among individuals with SCI, and potentially 
explain why some individuals with SCI experience multiple fractures while others experience 
only one or none. Therefore, this study will ascertain which individuals with SCI are at 




2.0 CHAPTER 2: BACKGROUND 
 
 
2.1 Spinal Cord Injury 
 
 According to the Rick Hansen Institute approximately 4000 Canadians sustain a SCI 
each year [33]. SCI can occur as a result of trauma (car accidents, gunshot wounds, falls, etc.) 
or disease (transverse myelitis, aneurysm repair, etc). Thirty five percent of traumatic spinal 
cord injuries occur as a result of car collisions, while 16.5% and 6.2% occur as a result of falls 
and other motor vehicle accidents, respectively [34]. SCI primarily affects young adults. The 
average age of injury is 37.6 years; the majority of injuries occur between the ages of 16 and 
30 [35], in which 80% of the SCIs occur in males [36]. However, the average age of injury is 
steadily rising due to an increased proportion of older adults experiencing SCI [21]. 
Individuals with SCI have a life expectancy of 25 to 30 years beyond their injury; the 
contributing causes of death most often are cardiac and respiratory dysfunction. Individuals 
with SCI are expected to reach normal life expectancy [37]. SCI is a multifaceted issue; it can 
occur in men or women, at any age, and at any segment with varying severities along the 
spinal cord.  
 SCI can be classified using the International Standards for Classification of SCI as 
either an incomplete injury or a complete injury. If sensory and/or motor functions are 
preserved below the neurological level, including the lower sacral segment, the injury is 
known as incomplete. With an incomplete injury, individuals will experience sensations at the 
anal mucocutaneous junction as well as deep anal sensation, and can voluntarily contract their 
external anal sphincter. A complete injury has no preservation of sensory and motor function 
in the lowest sacral segment, S4 and S5. However, when sensory and motor function below 
the neurological level and above S5 remains partially innervated with a complete injury this is 
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termed zone of partial preservation (ZPP). Tetraplegia (a preferred term to quadriplegia) 
refers to damage or impairment of motor and/or sensory function in the cervical segment 
resulting in loss of function in the arms, trunks, legs and pelvic organs. Paraplegia is the 
damage or impairment to neural elements in the thoracic, lumbar or sacral segments of the 
spinal cord. The neurological level of injury determines the degree of trunk, legs, and pelvic 
organ function preserved. However, since the cervical segment of the spinal cord has not been 
affected, the functions of the arms are spared in paraplegics [38]. 
 The majority of individuals with SCI have damage to both the upper and lower motor 
neurons. However, sometimes individuals with SCI can have damage to just the upper motor 
neuron or just the lower motor neuron. The upper motor neuron injury refers to injuries above 
the level of the anterior horn cell, resulting in a spastic type of paralysis. Conversely, damage 
to the lower motor neuron causes injury at or below the level of the anterior horn cell, which 
results in flaccid paralysis [36]. 
The severity and extent of the SCI is assessed by the American Spinal Injury 
Association (ASIA) impairment scale (AIS) (Table 1). Understanding the impairment scale is 
important because it is a single label describing the person’s functional impairment and 
anticipated abilities as a result of their SCI. AIS is a five-level standard grading system; one 
level for complete (AIS A), and three for incomplete (AIS B-D). The AIS is based on a 
systematic two-component neurological examination: 1) sensory examination, and 2) motor 
examination. The sensory level is examined by extensive testing of skins’ sensitivity to pin 
prick and to light touch. Dermatomes, areas of the skin that provide sensory input [39], are 
each scored as either normal, impaired or absent sensation. Likewise, the motor level is 
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determined by a manual muscle exam to test the strength of 10 key muscle groups on a six-
point scale (0 to 5).   
Table 1: AIS Impairment Scale 
AIS Grade Description 
A Complete; no sensory or motor function preserved in the sacral 
segments S4-S5 
B Incomplete; sensory but no motor function preserved below the 
neurological level and extending through the sacral segments S4-S5 
C Incomplete; motor function preserved below the neurological level; 
most key muscles have a grade < 3 
D Incomplete; motor function preserved below the neurological level; 
most key muscles have grade ≥3 






Bone is a complex connective tissue characterized by its unique hardness and rigidity. 
At a macroscopic level, bones are composed of cortical and trabecular compartments. Cortical 
(or compact) bone represents approximately 80% of the skeleton  [40]. Cortical bone is very 
dense; 80-90% of its volume is calcified tissue [41]. The shaft or diaphysis of the bone is 
primarily comprised of cortical bone. However, the metaphysis, the region below the growth 
plate, and the epiphysis, the area above the growth plate is composed mainly of trabecular (or 
cancellous) bone. Trabecular bone consists of thin interconnected trabecular struts, and 
represents approximately 20% of the skeleton [40]. Only 15-25% of the volume of trabecular 
bone is calcified. The function of trabecular bone is primarily metabolic, while cortical bone 
has primarily a mechanical function [41]. Bones also consist of an outer fibrous connective 
tissue called the periosteum and an inner membranous sheath called the endosteum. The 
periosteum contains an inner cambrium layer comprised of undifferentiated cells that become 
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bone forming cells, called osteoblasts, during osteogenesis. The endosteum contains surface 
cells called osteoblasts and osteoclasts that line the medullary cavity [41]. 
 Bone is comprised of functionally distinct cells called osteoblasts, osteoclasts, and 
osteocytes that are required to support the structural, biomechanical, and mechanical integrity 
of bone. Osteoblasts are bone forming cells which are responsible for the synthesis of 
osteoids, unmineralized bone matrix [41]. Once the bone matrix has been synthesized, the 
osteoblasts become embedded inside the calcified matrix and are converted to osteocytes [42]. 
Osteoclasts are large multinucleated bone lining cells up to 100µm in diameter and are 
responsible for bone resorption.  
 To maintain their regulatory functions, bone must respond to mechanical forces by 
undergoing bone remodelling and modeling. Bone remodelling and modeling are the 
processes by which bone is being turned over, allowing for the maintenance of the shape, size, 
and quality of the skeleton. This process is characterized by the coordinated actions of 
osteoblasts and osteoclasts. Bone is modeled and remodelled by the interactions of these cells 
to regulate mineral homeostasis, repair micro-fractures, and modify the bone’s structure in 
response to daily stresses imposed on the bone [42,43]. Understanding the basics of the bone 
remodelling cycle is critical, particularly when abnormalities occur in the cycle in common 
diseases that affect humans such as osteoporosis. Furthermore, understanding how bone 
remodelling is regulated is a key first step in the prevention and treatment of osteoporosis.  
There are four distinct stages in the remodelling cycle: activation, resorption, reversal, 
and formation (Figure 1). Activation involves the recruitment of osteoclasts. During the 
resorption phase, osteoclasts attach to the bone surface and begin to erode the matrix and 
minerals by acids and lysosomal enzymes. After the completion of osteoclastic resorption, a 
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reversal phase begins in which osteoblasts are employed to begin filling in the eroded cavities 
by laying down new bone. Once new bone has completely filled the resorbed cavities, a 
protective layer of lining cells are placed and a prolonged resting period begins until a new 
remodelling cycle is initiated [40]. Complete mineralization of a bone segment may take up to 
3 months [41]. During growth, the balance between bone formation and bone resorption is 
positive, resulting in an increase in bone mass. Bone formation and bone resorption are 
coupled until approximately 35 to 40 years, and then an increase in bone resorption relative to 
bone formation occurs, leading to bone loss [42]. Bone remodelling and modeling affect the 
external size and shape of bone as well as its internal micro-architecture by removing or 
depositing material from the surface of the bone. As a result, cortical and trabecular bone 
become thicker during growth and thinner during aging. 
 
Figure 1: Bone remodelling cycle (OC: osteoclasts; OB: osteoblasts) 
2.2.2 Changes in Bone with Aging 
 
During adulthood, the first change in the remodelling cycle that leads to bone loss is a 
decrease in bone deposition at the cellular level. When bone formation is less than bone 
resorption, a small amount of bone from the skeleton is removed with each remodelling cycle, 
resulting in bone loss and architectural deterioration in cortical and trabecular bone. The 
changes that occur in cortical bone are generally related to the size and diameter of the bone. 
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As long bones increase in length before either sex reaches puberty, the formation of bone on 
the periosteal surface widens the shaft of the bone, while a small volume of bone is 
concurrently removed on the endocortical surface. Since periosteal apposition exceeds 
endocortical resorption, the cortex of the long bone becomes thicker and farther from the axis 
[44]. Girls will achieve a smaller diameter because estrogen in girls inhibits periosteal 
apposition while promoting net bone formation on the endocortical surface, leading to a 
narrower inner diameter. In boys, androgen production increases bone formation on the 
periosteal surface, resulting in a larger diameter and thicker cortex (Figure 2) [44,45]. 
However, during aging, the amount of bone within the periosteal envelope is reduced by bone 
resorption on the endocortical, intracortical, and trabecular surfaces. Periosteal apposition 
offsets endosteal resorption more in men than in women which leads to a net loss of bone that 
is greater in women than in men [46-48]. In both genders, cortices become thin and porous  
 
Figure 2: Changes in cortical thickness in men and women during aging. Adapted from 
Seeman [45] 
 
while trabeculae thin and begin to disappear with aging [45,49]. The trabecularization of the 
cortex caused by the increase in cortical porosity, increases the surface to volume ratio so that 
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remodelling occurs vigorously, predisposing the bone to buckling, microdamage, and 
ultimately fractures [43,50].   
Age-related changes can also be seen in trabecular bone. These include a decrease in 
bone volume, bone surface density, trabecular thickness, trabecular number, and connectivity 
[49,51]. Trabecular bone has more surface than cortical bone; there are more remodelling sites 
per volume, resulting in a greater proportion of trabecular bone turn over [52]. In men, 
trabecular bone loss occurs mainly by thinning rather than loss of connectivity (fewer number 
of trabeculae), while in women, trabecular bone loss occurs mainly by loss of connectivity 
[43,48,53].  Loss of connectivity is a result of rapid bone loss that occurs in midlife in women 
due to estrogen deficiency. Estrogen deficiency increases bone resorption by osteoclasts and 
reduces bone deposition by osteoblasts, producing a high bone turnover rate [43]. Trabecular 
struts are thinned and many begin to disappear, particularly horizontal struts, causing the loss 
of connectivity [49], which in turn reduces bone strength and increases the risk of fracture. 
2.2.3 Osteoporosis 
 
Osteoporosis is a skeletal disorder characterized by a reduction in bone mass and a 
deterioration in bone micro-architecture, which clinically results in increased bone fragility 
and fracture risk [54]. Osteoporosis mainly affects post-menopausal women; however both 
younger men and women may also be affected [55].  In Canada, two million Canadians suffer 
from osteoporosis; 1 in 4 women and 1 in 8 men [56].  
Currently, the diagnosis of osteoporosis and fracture risk is primarily based on 
assessing areal bone mineral density (aBMD) by dual energy x-ray absorptiometry (DXA) 
[15,16]. Osteoporosis is defined as having an aBMD at the femoral neck of 2.5 or more 
standard deviations (SD) (T-score ≤ 2.5 SD) below the peak bone mass for young adults. 
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Recent 2010 guidelines for the diagnosis and management of osteoporosis [17]  in Canada 
have suggested that certain clinical factors increase the risk of fracture independent of aBMD 
and proposed that managing osteoporosis should focus on preventing fragility fractures and 
their harmful effects rather than treating low aBMD. Currently, two tools are available in 
Canada for estimating 10-year risk of a major osteoporotic fracture and both tools incorporate 
clinical risk factors. The Canadian Association of Radiologists and Osteoporosis Canada 
(CAROC) tool stratifies men and women over the age of 50 into low (<10%), moderate (10-
20%), or high (>20%) risk for major osteoporotic fracture within 10 years. An initial risk 
category is provided based on age, sex, and femoral neck T-score. However, certain clinical 
factors such as the presence of a prior fragility fracture after age 40 and prolonged 
glucocorticoid use raises the individual’s fracture risk to the next higher risk category. The 
World Health Organization (WHO) Fracture Risk Assessment tool (FRAX) varies from the 
CAROC tool because it is based on a more complete set of clinical risk factors: sex, age, 
BMI, prior fracture, parental hip fracture, prolonged rheumatoid arthritis, smoking, alcohol 
intake, and aBMD at the femoral neck. These diagnostic criteria are used in predicting 
fracture in post-menopausal women and men over the age of 50 [15,16]; therefore, it is not 
clear how to apply these diagnostic criteria in individuals with SCI. The majority of 
individuals with SCI fall into the osteoporotic group. Therefore, there is ambiguity over an 
appropriate diagnostic criteria and intervention protocol for individuals with low bone density 
such as individuals with SCI.  
2.3 SCI and Osteoporosis 
 
SCI is a condition known to be associated with a substantial amount of bone loss 
following the injury, predisposing individuals with SCI to an increased fracture risk. Various 
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cross-sectional studies and prospective studies have reported a significant reduction in BMD 
in the lower limbs among individuals with SCI compared to controls (Table 2). However, 
there is immense variability between studies in the amount of bone loss that occurs following 
a SCI. For example, prospective studies have reported that BMD at the knee decreases 
between the ranges of 1.1% to 47% per year [2,3,20,57-60], suggesting individual variability 
in the amount of bone loss following a traumatic SCI. Among individuals with SCI, the most 
common site of bone loss is at the distal femur and proximal tibia [61]. Studies have 
demonstrated that individuals with SCI can lose up to 70% and 52% of BMC in the distal 
femur and proximal tibia, respectively [1,2,30,61].  
Bone loss generally involves the lower extremities in individuals with paraplegia, 
although, bone loss has been noted in the upper extremities in addition to the lower 
extremities among individuals with tetraplegia [2,59,62]. Bone demineralization in the upper 
extremity has been found to be significantly different when comparing paraplegic and 
tetraplegic individuals [60,63]. A 12-month prospective cohort study demonstrated that 
tetraplegics had a trabecular BMD loss of 28% and 15% and cortical BMD loss of 3% and 4% 
at the radius and ulna, respectively. No significant changes were reported in trabecular or 
cortical BMD of the radius and ulna in paraplegics [20]. Contradictory results have been 
reported regarding the changes that occur in the lumbar spine. Changes in the lumbar spine 
have been found to increase, decrease, and remain unchanged in individuals with SCI [6,59-
61,64,65]. 
The rate of bone loss after SCI varies over time. Initially, during the acute phase of 
SCI, BMD in the lower extremity decreases at a rate of 1-2% per week [1,2,57,66]. The rapid 
bone loss is attributed to an increase in osteoclastic activity [2,67,68]. Following 1-2 years 
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post-injury, bone resorption markers begin to return to normal [67] and bone loss in the lower 
extremity decreases to a rate of 1% per month [57,66]. Approximately 2 to 3 years after SCI, 
a steady state between bone resorption and bone formation is established [3,58,69]. In a 
prospective study, Biering-Sorensen et al demonstrated that after a SCI, new steady state for 
bone mineral content (BMC) in the femoral neck and proximal tibia were achieved after 
decreasing by 30-40% and 50-60%, respectively [60]. Although this study had a longitudinal 
design, the sample size was very small and included only six men and two women. In 
contrast, a few cross-sectional studies have reported that BMD in the lower extremity may 
continue to decline at a rate of 1% per year [57,66]. Whether bone remodelling re-establishes 
at a new steady state after SCI remain controversial.  
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Age ± SD 
Years Post Injury 













PS 6 men; 2 women; 
18-49 years 
9 days-53 months 8 Complete 
1 Incomplete 
FN, PT FN: 30-40% ↓/30-53 months 
PT: 50-60% ↓/30-53 months 
Dauty et al, 
2000 [61] 
CS 31 males 
36 ± 12.3 




DF: 70% ↓ in BMD 
PT: 52% ↓ in BMD 
FN: 30% ↓ in BMD 
FT: 39% ↓ in BMD 
De Bruin et 
al, 2005 [3] 
PS 9 men; 1 woman 
40.9 ± 19.7 
5 weeks 4 Complete 
6 Incomplete 
DT, DR Trabecular and Cortical of Radius: 
no change 
DT 
Trabecular: 40% ↓ in 3 years 
Cortical: 11% ↓ in 3 years 
De Bruin et 
al, 2000 
[58] 
PS 9 men 
32.4 ± 9 
5 weeks 4 Complete 
5 Incomplete 
DT, TS Trabecular: 35.5% ↓ within 2 
years 
Cortical: 12.9% ↓ within 2 years 
Demirel et 
al,1998 [62] 
CS 32 men; 9 women 
35.8 ± 12.7 
2-30 months 
9.5 ± 4.5 months 
21 Complete 
20 Incomplete 
LE Paraplegics: ↓ 2.19 ± 3.5 
Tetraplegics: ↓ 2.50 ± 0.55 
Dionyssiotis 
et al, 2006 
[4] 
CS 39 men, 2 groups: 
A: 38.22 ± 15.6 
B: 39.47 ± 13.81 
A: 5.97 ± 5.9 years 
B: 5.65 ± 5.8 years 
Complete  TS, DT BMDtrab: 58% ↓ in A; 49% ↓ in B 
BMDtot: 47% ↓ in A; 45% ↓ in B 
THIcort: 20% ↓ in A; 17% ↓ in B 
Eser et al, 
2004 [19] 
CS 89 men 
41.5 ± 14.2 
12.0 ± 11.3 years Complete  DT, DF, 
TS, FS, 
PT 
BMDtot: 45% ↓ tibia; 57% ↓ femur 
CSAcort: 30% ↓ tibia and femur 
THIcort: 35% ↓ tibia; 33% ↓ femur 
Eser et al, 
2005 [30] 
CS 89 men; 10 women 
41.5 ± 13.7 
2 months – 24.5 
years 
12.3 ± 11.6 years 
Complete DT, DF, 
TS, FS, 
PT 
DF: 54% ↓ BMD  in first 5 years 
DT: 73% ↓ BMD in first 7 years 
vBMD of epiphysis in LE best 








Age ± SD 
Years Post Injury 







(compare to control or other 
interpretation) 
Finsen et al, 
1992 [70] 
CS 19 men 
15-64 years 
7 months- 33 years  DT  DT diaphysis: ↓ 26 % in BMD 





PS 27 men; 2 women 
19-59 years 
Undefined 10 Complete 
19 Incomplete 
TS, DT BMDtrab: 15%↓ in 12 months 





CS 39 men 
42 ± 10.8 
0.9 – 34 years 
12.0 ± 10.8 years 
Complete FS, DF, 
TS, DT 
In 30 months 
DF: BMDtrab: 1.30%↓ 
FS: BMDcort: 0.17% ↑ 
       pSSI: 1.72% ↓ 
DT: BMDtrab: 1.67% ↓ 
DS: BMDcort:  0.48% ↓ 
       CTh: 0.73% ↓ 
       pSSI: 0.55% ↓ 
Garland et 






< 40 years 
 
31 women, 3 
groups: 
≤ 30 years 
30-50 years 
> 50years 
Acute: 114 days 











DF: 37% ↓ 10 years after 
PT: 36% ↓ 10 years after 
 
≤ 30 years: 38%↓ 
30-50 years: 41% ↓ 
> 50years: 47% ↓ 
Garland et 











28.1 ± 0.78 
5 years  
3649.6  ± 326.6 
days 
 











DF: 37% ↓ 
PT: 36% ↓ 
 
 
DF: 13% ↓ in 16 months 









Age ± SD 
Years Post Injury 












PS 27 men; 4 women 
39.7 ± 10.6 
14.6 ± 8.7 years Complete  Spine, hip, 
DF, PT, 
LE 
Spine: 0.3% ↑/year 
Hip: 0.4% ↓/year 
DF: 1.1% ↓/year 
PT: 1.5% ↓/year 




PS 31 women; 3 
groups 
≤ 30 years  
31-50 years 
> 50 years 
 
5.7 ± 2.3 years 
16.1 ± 9.4 years 
28.9 ± 11.4 years 
Complete Knee, Hip, 
Spine 
Knee: 38-47% ↓ in BMD/year 
Hip: 18-25% ↓ in BMD/year 
Spine: -2 to 15% ↑ in BMD/year 
Modlesky et 
al, 2005 [5] 
CS 8 men 
33.1 ± 9.2 
2.3 – 20 years 
7.4 ± 6.0 years 
Complete  FS aBMD: 25% ↓ 
THIcort: 27-47% ↓ 
Cortical volume: 24% ↓ 




CS 10 men 
34.6 ± 9.2 
2.3 – 20.1 years 
8.5 ± 6.6 years 
Complete  DF, PT DF 
appBV/TV: 27% ↓ 
appTb.N: 21% ↓ 
appTb.Sp: 44% ↑ 
appTb.Th: 8% ↓ 
PT 
appBV/TV: 20% ↓ 
appTb.N: 20% ↓ 
appTb.Sp: 33% ↑ 
appTb.Th: no difference 
aBMD: 43% ↓ 






CS = cross-sectional study; PS = prospective study 
DT = distal tibia; DF = distal femur; TS = tibial shaft; FS = femoral shaft; FN = femoral neck; FT = femoral trochanter; PT = proximal 






Age ± SD 
Years Post Injury 







(compare to control or other 
interpretation) 
 Slade et al, 
2005 [73] 
CS 19 women, 3 
groups 
42.6 ± 4.66 
54.5 ± 7.7 
23.0 ± 2.55 
≥ 2 years 
12.2 ± 8.14 years 
14.17 ± 11.9 years 
5.6 ± 2.33 years 
Complete DF, PT DF 
appBV/TV: 30.9% ↓ 
appTb.N: 26.5% ↓ 
appTb.Sp: 61.7% ↑ 
appTb.Th: 6.8% ↓ 
PT 
appBV/TV: 23% ↓ 
appTb.N: 18.5% ↓ 
appTb.Th: 5.8 ↓ 
Zehnder et 
al, 2004 [6] 
CS 100 men 
38 ± 0.97 
1 month – 
29.5years 
10.4 ± 0.79 years 




BMD ↓ with time at all LE sites 
Fractures occur after trabecular 
bone lost had levelled off 
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2.3.1 SCI and Bone Geometry 
 
Changes in bone micro-architecture and geometric structure have also been reported in 
conjunction with loss of bone mass after SCI (Table 2). In men with complete and long-term 
SCI, trabecular bone micro-architecture in the distal femur and proximal tibia was 
significantly deteriorated compared with control subjects. Men with SCI had fewer trabeculae 
that were further apart which resulted in a lower ratio of bone volume to total volume 
(BV/TV) [72]. Similar findings have been reported in women with complete SCI compared to 
ambulatory women [73]. The deterioration of trabecular micro-architecture in women with 
SCI was reported to be greater than in postmenopausal women with osteoporosis. Middle-
aged ambulatory postmenopausal women who were not taking estrogen or bone medications 
did not show the deterioration of trabeculae that was seen in women with SCI [73]. 
Furthermore, an interaction between mechanical unloading and low estrogen levels was 
reported; postmenopausal women with SCI had 34% greater trabecular spacing in the tibia 
than premenopausal women with SCI [73]. Thus, immobilization following SCI significantly 
reduces bone architecture around the knee in both men and women. Changes in bone area and 
bone geometry after SCI have also been reported [74,75]. Cortical thickness has been shown 
to remarkably change in the tibia and femur after a SCI. In a cross-sectional study, men with 
complete SCI had thinner cortical walls by 19.78% compared to the control group [4]. The 
findings in this study were consistent with two previous cross-sectional studies which 
reported a reduction in cortical thickness by 33-35% [19] and 27-47% [5]. Consequently, the 
decrease in cortical thickness was attributed to an increase in endosteal resorption, occurring 
at approximately 0.3mm per year [4,19]. Another study found that individuals with SCI with a 
lower extremity fragility fracture had a lower area moment of inertia in the tibia compared to 
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individuals with SCI without a fracture and able-bodied control [74], indicating that the 
ability of the bone to resist bending load is much lower among individuals with SCI with a 
fracture. Ultimately, the distribution of bone mineral around the bone’s bending axis has been 
reduced [74]. Changes in bone quality after SCI may contribute to a high incidence of lower 
extremity fractures. Therefore, analysis of bone structure, combined with measurements of 
aBMD may improve the ability to determine fracture risk among individuals with SCI. 
2.3.2 Which Bone Strength Parameters are Important? 
 
 There are many bone strength parameters that can be measured, but selecting which 
ones may be of clinical importance is difficult. Many studies in men, women, and children 
have examined the association between bone strength parameters and fracture risk.  In healthy 
adults, MacIntyre et al [76] demonstrated gender and age-dependent increases in average hole 
size (HA). Furthermore, pQCT-based trabecular structure variables were related to bone 
strength in vitro [77]. Women with a history of forearm fractures had significant differences 
in trabecular bone structure than women with similar aBMD but no history of fracture [26], 
indicating that structure-based measurements, such as HA may be useful for identifying those 
at higher risk for fractures such as individuals with SCI. Average hole size is the average area 
of each hole represented by the marrow space. As trabecular struts become thinner and begin 
to disappear, hole size increases. As a result, trabecular bone becomes weak and unstable 
leading to subsequent fractures.   
Small changes in cortical bone have been shown to make a large difference in bone 
strength [78]. In 677 healthy young men with childhood fractures, prevalent fractures were 
associated with decreased cortical thickness. Childhood fractures were associated with a 
thinner cortex and smaller bone size (periosteal circumference), while fractures occurring later 
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than 15 years of age were associated with a thinner cortex and wider endosteal circumference, 
with no change in periosteal bone size [79]. This suggests that there are different mechanisms 
of fracturing during childhood versus in adult life.  When a child fractures its bones, it may 
disturb the natural growth cycle causing a thinner cortex and suboptimal acquisition of peak 
bone mass resulting in an increased risk of fracture. 
Cross-sectional moment of inertia is an indicator of bone’s architectural design (how 
mass is distributed about the bones’ central axis) which is able to predict the ability of bone to 
resist bending. For example, when bone mass is distributed progressively further from the axis 
(resulting in wider bones), the cross-sectional moment of inertia increases and bone’s ability 
to resist bending forces also increases, resulting in lower chances of fracturing [80]. Polar 
moment of inertia is also a biomechanical term that describes the ability of bone to resist 
torsion. A bone with a large polar moment of inertia will resist twisting caused by torque. 
Both polar moment of inertia (OR=2.6, 95% CI=1.1-6.1, p<0.05) [81] and cross-sectional 
moment of inertia (HR=2.2, 95% CI= 1.4-3.3) [80] were found to be significantly related to 
fracture risk. In addition, polar moment of inertia at the ultra-distal tibia appears to be lower 
in postmenopausal women who have sustained a forearm fracture compared to age-matched 
controls [81].  
 Buckling ratio defined as the maximum distance from the center of mass to the medial 
or lateral edge of bone, divided by the average cortical thickness has also been found to 
correlate with fracture risk. In a retrospective study examining structural variables as assessed 
by DXA, fractures due to severe trauma were best correlated with femoral neck buckling ratio 
in postmenopausal women (OR=1.2, 95% CI=1.04-1.5) and intertrochanteric buckling ratio in 
men (OR=1.4, 95% CI=1.2-1.6) [81]. An attractive feature of assessing buckling ratio is that it 
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presents a possible mechanism to explain why greater bone loss and greater expansion of 
bone diameter reduces BMD. 
 To our knowledge, there are no studies investigating the relationship between fracture 
prevalence and average hole size, cortical thickness, cross-sectional moment of inertia, polar 
moment of inertia, and buckling ratio among individuals with SCI. Since these indices of 
bone strength have been found to be clinically important correlates of fracture risk in able-
bodied men and women, it may be useful to investigate their association with fragility 
fractures sustained in individuals with SCI. 
2.3.3 Mechanism of Bone Loss in SCI 
 
The rapid loss of BMD and bone strength occurs invariably among conditions of 
immobilization such as SCI. According to Wolff’s law, the direction, rate and magnitude of 
mechanical loading on bone has an influence on how bone remodelling will respond [82]. For 
this reason, the structural integrity of bone changes in response to gravity and mechanical 
stress. However, when bone is subjected to mechanical unloading, uncoupling occurs between 
bone formation and bone resorption. Individuals with SCI will experience an imbalance 
between high bone resorption and low (or normal) bone formation within the first week of 
injury which peaks around weeks 10 to 16 [6,67,68]. Therefore, individuals who experience 
minimal or no mechanical loading have excessive osteoclastic resorption and an inhibition of 
osteoblastic activity. Studies have also reported that in paralyzed extremities there is an 
increase in IL-6 (interleukin-6). IL-6 is a well-known cytokine which has been suggested to 
enhance osteoclastic formation and activity [83]. The enhanced osteoclast activity has been 
reported to begin one month after the injury [6,84]. IL-6 may be produced in large amounts to 
promote increases in OC-like (osteoclast-like) cells in areas below the lesion level. Due to the 
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increase in OC levels, there is an immediate increase in urinary hydroxyproline excretion 
which marks an increase in bone resorption [85]. The dramatic elevation of bone resorption 
exceeds osteoblastic activity, resulting in a higher bone turnover rate and poor bone quality. 
Mechanical unloading may not be the only factor contributing to bone loss; a study showed no 
increases in BMD following mechanical loading [86]. Other factors include neurological [4] 
and hormonal changes [6]. Each of these factors may independently influence bone 
metabolism affecting the overall quality of the bone. 
2.3.4 Risk Factors Associated with Bone Loss in Individuals with SCI 
 
Several factors appear to influence the severity of bone loss among individuals with 
SCI. Modifiable and non-modifiable risk factors for osteoporosis in SCI include low BMI 
(body mass index < 19kg/m
2
), age, gender, lifestyle behaviours such as alcohol consumption, 
and impairment variables such as the level of injury (LOI), duration of injury (DOI), 
completeness of injury, [29,87].  BMI has been found to be a reliable correlate of osteoporosis 
among individuals with SCI. Garland et al reported that for each unit increase in BMI, the 
odds of being osteoporotic decreased by 11.29%; however they did not determined if BMI is 
linked to fractures [87]. Interpreting this finding is difficult because characterizing overweight 
and obesity using BMI in the SCI population is unreliable. BMI defined for the able-bodied 
population fail to identify individuals with SCI who are obese. Studies have reported that the 





However, the percent fat mass ranges from 27.5% to 36.3% [88-90] which is consistent with 
obesity fat mass values (>25%) in the able-bodied population [92], suggesting that BMI 
underestimates obesity in the SCI population, leading to a failure in the identification of 
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persons with SCI who are actually obese. Consequently, lower BMI (>22kg/m
2
) cut-off points 
have been proposed in identifying individuals with SCI at high risk of obesity [91]. 
The current literature on alcohol consumption and the severity of bone loss among 
individuals with SCI is mixed. One study found that individuals drinking moderate amounts 
of alcohol were less likely to be considered osteoporotic. Unfortunately, the data for alcohol 
use only approached significance but was not established as a significant correlate of high 
amounts of bone loss [87]. There are only a few studies showing that modifiable factors such 
as BMI and alcohol consumption are risk factors for osteoporosis. As a result, further 
investigations examining the role of these risk factors with bone loss needs to be carried out.  
The level of spinal cord injury has been reported to be a strong correlate of bone loss 
in the knee regions among individuals with SCI [29]. Many studies have demonstrated that 
tetraplegics lose more bone throughout the skeleton than paraplegics [2,61,62,67,70,93]; 
however the amount of bone loss in the sublesional area was similar between both groups 
[20,61,62,93]. Furthermore, a decrease in bone mass may be more severe among individuals 
with a motor complete SCI (AIS A and B) [2,29,62,87]. In a cross-sectional study of 46 males 
with SCI, Sabo et al [64] reported that males with a complete SCI had significantly lower 
BMD in the lumbar spine compared to those with an incomplete SCI.  
Duration of injury is another factor that has been shown to influence bone loss [62,70]. 
A SCI twin study found that bone mineral content (BMC) and BMD in the leg declined at a 
continuous rate with duration of injury and appeared to be independent of age [94]. However, 
this is inconsistent with other studies which found no correlation between bone loss and 
duration of injury [95,96]. The inconsistent results may be due to the skeletal heterogeneity in 
the respective sample population, which were not evident in the twin study. 
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Age and gender have also been shown to contribute to bone loss in individuals with 
SCI. A cross-sectional study stratifying women with SCI into three groups according to age (≤ 
30 years; 31-50 years; >50 years) found that BMD in the knee decreased by 38%, 41% and 
47% and BMD at the knee decreased by 18%, 25%, and 25%, respectively compared to the 
corresponding control groups [59]. Kiratli et al [75] found similar results reporting a 
correlation between age and BMD in men (19-81years) and women (21-83 years) with SCI. 
With regards to gender, women with SCI have been reported to have lower BMD in the knee, 
hip and spine compared to males with SCI [57]. Contrary to the findings of Kiratli et al [75] 
and Garland et al [57,59], a cross sectional study found that age and gender were not related 
to bone loss in individuals with SCI [62]. The differences in outcomes found in these studies 
may be attributed to the age of the sample population. The studies that reported a relationship 
between age and gender of the participants and bone loss among individuals with SCI 
recruited older participants, while the study reporting no relationship recruited younger 
participants and premenopausal women. The study quality to date does not provide enough 
information to determine whether age and gender may influence bone loss among individuals 
with SCI.  
There are many potential modifiable and non-modifiable risk factors that may 
contribute to bone loss (Table 3); however they have not been clearly established. Based on 
the current literature, age, gender, completeness of injury, and duration of injury may be the 
most important correlates of bone loss and need to be studied further to accurately understand 





Table 3: Modifiable and Non-modifiable Risk Factors for Osteoporosis among 
Individuals with SCI 





Level of injury 





2.4 Risk Factors Associated with Fractures in Individuals with SCI 
 
One clinical consequence of bone loss following SCI is an increased risk of fracture. 
In particularly, individuals with SCI are susceptible to low-energy fracture known as fragility 
fractures. A fragility fracture occurs as a result of minor trauma that would not normally cause 
a fracture such as transferring from chair to bed or colliding into unseen objects 
[8,9,12,30,97,98]. Thus, most of these fractures occur during activities of daily living. An 
individual with SCI has twice the risk of suffering from a lower extremity fracture than an 
able-bodied person in their lifetime [7]. Cross-sectional studies have reported a high 
prevalence of lower extremity fragility fractures among individuals with SCI ranging from 
1% to 34% (Table 4). The prevalence may be underestimated as individuals with SCI may not 
seek medical attention for fracture because they are unaware of their fracture [11]. Fractures 
most commonly occur at the distal epiphysis of the femur and tibia, and the proximal 
epiphysis of the tibia [1,7,8,11-13,20]. Spiral fractures commonly occur at the diaphysis while 
bending fracture occur in the distal femur and proximal tibia [98]. Fracture rates have been 
reported to increase from 1% per year in the first year to 4.6% per year in individuals with 
SCI for more than 20 years [6]. Complications from fractures include pressure sores, 
infections, delayed union and illness, resulting in a diminished quality of life [8,10,12]. 
There are many factors that affect fracture risk in individuals with SCI. Fractures have 
been reported to occur more commonly in individuals with a complete SCI compared to an 
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incomplete SCI [9,11]. Individuals with a complete SCI lose more bone than individuals with 
an  incomplete SCI [29,64], therefore individuals with complete SCI are more prone to 
fractures. In addition, paraplegics fracture more than tetraplegics [10]. A possible reason 
could be that paraplegics use manual chairs and transfer independently more often, which 
may result in more falls. BMD can also be used to quantify fracture risk in individuals with 
SCI by determining the number of SD below young adult mean BMD. For every 0.1g/cm
2
 
decrease in BMD at the femoral neck, fracture risk increased 2.2 times [14]. In studies 
comparing individuals with SCI who have a history of fractures to those who do not, duration 
of injury was also reported to be a strong correlate of fracture risk [6,14]. Other risk factors 
for fracture risk include female gender [7] and flaccid paralysis [8,11,99]. Individuals with 
lower motor neuron lesions (flaccid paralysis) were more prone to develop fractures than 
those with upper motor neuron lesions (spastic) [11,30] . Spasticity seems to preserve bone 
mass, resulting in a reduced fracture risk. However, other studies have not established an 
association between muscle spasticity and BMD [58,60]. 
Fragility fractures are a major problem in the SCI population; they lead to increased 
morbidity and prolonged immobilization, resulting in further deterioration of bone. Therefore, 
it is important to maintain or improve bone strength among individuals with SCI. Risk factors 
along with bone loss may distinguish individuals with SCI and prior fracture from those with 
no history of fracture. Larger prospective studies are needed to further examine risk factors 
related to bone loss and fracture so that future studies can better understand the 
pathophysiology of fractures in order to identify persons at risk of fragility fractures and 
implement appropriate treatment interventions prior to fracture onset. In addition, little is 
known about the effects of prior fragility fractures on individuals with SCI. A prior (or recent) 
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fracture confers one of the strongest risk factor for future fracture in postmenopausal women 
and men over the age of 50 years [17]. Whether or not fracture history improves our ability to 


















Mean Age ± SD 
Years Post 
Injury 







al, 2005 [9] 
CS Retrospective 1363 (total)  X-rays, 
Medical 
Charts 
 11% (6% lower 
extremity fracture) 
Freehafer et 
al, 1983 [12] 




32 years 8% 
Ingram et al, 
1989 [13] 





Lazo et al, 
2001 [14] 










et al, 1981 
[8] 
CS Retrospective 578 (total) 
4-71 years  
(mean 31) 






et al, 1998 
[7] 
CS Prospective 309 Men; 129 
Women 
17-80 years 
12 years Self-report  2%/yr 
Zehnder et 
al, 2004 [6] 
CS Prospective 100 Men 
38±0.97 
10.4±0.79 















incidence 2.2%/year  
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2.5 Diagnosing Osteoporosis and Fracture Risk in SCI 
 
2.5.1 Assessment of aBMD using Dual Energy X-ray Absorptiometry 
 
There is currently no specific guideline or screening protocol for assessing 
osteoporosis among individuals with SCI. DXA measurements of aBMD of the knee and 
screening for fracture risk factors (age at injury < 16 years, alcohol intake > 5servings/day, 
BMI < 19, DOI ≥10 years, female gender, motor complete, paraplegic, and prior fragility 
fractures) have been recommended for establishing fracture risk in individuals with SCI [32]. 
In able-bodied postmenopausal women and men over the age of 50, DXA at the hip along 
with clinical risk factors is the standard diagnostic method for assessing osteoporosis and 
fracture risk. DXA is a two dimensional non-invasive imaging technique that measures aBMD 
(g/cm
2
) regionally at the lumbar spine, hip, or wrist, as well as the whole body. DXA can also 
be used to measure BMC, lean mass and fat mass. Radiation exposure is extremely low for 
DXA scans, approximately 10-30µSV, which is much lower than that experienced annually 
from natural background sources, 2400µSV [100]. Among individuals with SCI, the fracture-
prone sites are the proximal femur and distal tibia. A validation study was recently conducted 
to determine the reliability of DXA scanning protocol at measuring knee BMD, specifically 
the proximal tibia and distal femur in individuals with SCI. The knee BMD measurements 
were reported to be very reliable with correlations of greater than 0.97 and 0.87 in the distal 
femur and proximal tibia, respectively [101]. When examining the precision of the DXA, 
ISCD recommends that aBMD testing be done on 15 patients three times or 30 patients two 
times with repositioning of the limbs for each scan to achieve statistical significance. For this 
study, each of the four technicians only conducted one scan for each participant which may 
not accurately assess precision error [102].  
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Although aBMD is considered to be a practical measure of bone strength, it does not 
provide any information on bone geometry that may contribute to fracture risk such as cortical 
and trabecular micro-architecture, and bone size and shape. The projectional nature of the x-
rays produced by the DXA scan combines the influence of bone density and geometry on 
bone strength to give aBMD, rather than providing volumetric measurements of bone density 
[103]. Limitations in using DXA in individuals with SCI may include limited accessibility, 
longer scanning time, increased staffing during scans, and the need for ceiling-mounted 
hydraulic lifts need to be installed [104]. 
2.5.2 Assessment of Bone using Peripheral Quantitative Computed Tomography 
 
Peripheral quantitative computed tomography (pQCT) is a non-invasive diagnostic 
technique that provides a three-dimensional (3D) image allowing for vBMD and cross-
sectional bone dimensions to be measured. pQCT is able to differentiate between cortical and 
trabecular bone, estimate bone strength, and assess bone geometry [18].  pQCT may be a 
useful technique in assessing fracture risk because in addition to bone density, bone structure 
and geometry may also contribute to the integrity of the bone. Currently, there have been a 
few studies conducted on individuals with SCI examining bone geometry using  pQCT 
[3,19,20,30,58,69,71,74]. Individuals with SCI experience a reduction in cortical thickness, 
reduced trabecular vBMD, and a decrease in polar moment of inertia [19]. Therefore, 
trabecular and cortical micro-architecture may be helpful in predicting fracture risk among the 
SCI population.  Benefits of using pQCT among individuals with SCI include low doses of 
radiation and facilitation of transfer is not required; individuals with SCI can remain in their 
wheelchair during the scan, resulting in a decrease in burden upon the patient, a decrease in 
clinic time, and thus a reduction in healthcare costs.  pQCT is a useful technique that provides 
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information on bone quality, which could potentially be related to bone fragility; however this 
technique is primarily being used in research settings and has not yet been adapted in the 
clinical setting.  
2.5.3 Fracture Threshold and Fracture Break Point 
 
Bone loss after SCI is said to reach a ‘fracture threshold’. Fracture threshold is defined 
as BMD in a specific skeletal site below which osteoporosis-related fractures begin to occur, 
while fracture breaking point are values at which the majority of fractures occur [29,105]. 
Fracture threshold may be an alternative method for evaluating fracture risk. Fracture 
thresholds established for postmenopausal women at the spine, femoral neck and 




, and 0.92 kg/m
2
, respectively 
[106]. However, the concept of fracture threshold in able-bodied osteoporotic postmenopausal 
women has been discarded because a meta-analysis demonstrated a linear relationship 
between aBMD and fracture risk. In the able-bodied population, fracture threshold can predict 
fracture risk, but is unable to identify those who will fracture [107]. However, the use of 
fracture threshold is gathering support among SCI physicians and researchers [32], based on 
data from studies identifying aBMD and vBMD threshold values below which there is an 
increase in lower extremity fragility fractures among individuals with SCI [29,30]. Low 
aBMD of distal femur and proximal tibia are able to distinguish individuals with SCI with and 
without a lower extremity fracture. Garland et al [29] reported DXA-based aBMD fracture 
threholds of 0.78g/cm
2
 and a fracture breaking point to 0.49g/cm
2
 at the knee among 
individuals with SCI which is significantly smaller than the fracture thresholds in 
postmenopausal women, suggesting other factors could explain the differences. Risk factors 
that should be considered include low BMD (<0.78g/cm
2
), complete paraplegia, female 
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gender, prior fracture, duration of injury, and age [29]. Fracture thresholds have not yet been 
established for postmenopausal women at the knee, therefore a direct comparison of fracture 
threshold around the knee cannot be determined.  
Recently, a cross-sectional study was conducted by Eser et al [30] suggesting that 
volumetric trabecular BMD (vBMD) of the lower extremity is the best parameter to identify 
those at risk of fracture and determine fracture threshold among individuals with SCI. 
Fractures occurred among individuals with SCI with trabecular vBMD of 114mg/cm
3
 for the 
femoral distal epiphysis and 72mg/cm
3
 for the tibial distal epiphysis. These vBMD values 
correspond to 46% and 29% of the femur and tibia mean aBMD values, respectively, of an 
able-bodied population [30].  
The current literature to date on fracture threshold among individuals with SCI is 
limited to two studies. In addition, the aBMD fracture threshold reported by Garland et al [29] 
were obtained from men and included a small sample size (n=18), while the study by Eser et 
al [30] included individuals with just motor complete SCI. Therefore, until fracture threshold 
is validated, its utility remains uncertain whether it could help identify individuals with SCI at 
high risk of fracture. 




Bisphosphonates are the primary drug prescribed for osteoporosis and other bone-
related diseases. Etidronate (Didrocal®), alendronate (Fosamax®), risedronate (Actonel®) 
and zoledronic acid (Aclasta®) are bisphosphonates that are currently approved by Canada for 
the prevention and treatment of postmenopausal osteoporosis. They are anti-resorptive agents 
that have been reported to inhibit bone resorption and reduce activation frequency of 
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osteoclasts in conditions characterized by increased bone resorption such as postmenopausal 
osteoporosis, glucocorticoid-induced osteoporosis, Paget’s disease, and male osteoporosis 
[108]. 
2.6.1.1 Mechanism of Action 
 
Bisphosphonates can be classified into two groups: non-nitrogen based 
bisphosphonates; and nitrogen-based bisphosphonates.  Non-nitrogen based bisphosphonates 
(Etidronate) are metabolically incorporated into non-hydrolysable analogues of adenosine 
triphosphate (ATP). The accumulation of toxic analogues to ATP within the OC inhibits OC 
function and may cause premature apoptosis of OC. Nitrogen based bisphosphonates 
(Alendronate, Risedronate, and Zoledronic Acid) target the mevalonate pathway which in turn 
inhibits OC resorptive activity and stimulates OC apoptosis (Figure 3) [108].  
 
Figure 3: The pathway by which bisphosphonates affect osteoclasts 
2.6.1.2 Bisphosphonate Therapy among Individuals with SCI 
 
Oral bisphosphonates (alendronate) have been assessed among individuals with 
chronic SCI in two randomized control trials. In the first study conducted by Zehnder et al 
[109], subjects received alendronate (10mg daily) and elementary calcium (500mg daily) and 
compared them to control subjects receiving elementary calcium (500mg daily) over a 24 
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month period in 55 men with motor complete SCI (AIS A or B).  BMD was maintained in the 
tibia epiphysis and total hip in the treatment group but was significantly decreased in the 
control- group. The lumbar spine BMD increased in both the treatment and control group, 
while there was no significant change in radial BMD. Biochemical markers of bone resorption 
were also reported to decrease among the treatment group which verified the results acquired 
by DXA. 
The second randomized control trial conducted by Moran De Brito et al [110] 
examined the impact of alendronate (10mg daily) plus calcium (1000mg daily) versus calcium 
(1000mg daily) for 6 months in paraplegic and tetraplegic men (n=15) and women (n=4) with 
chronic SCI (AIS A, B or C). The results from this study demonstrated that alendronate and 
calcium have no significant impact on lower extremity BMD; however there was a mean 
increase in upper extremity BMD among the treatment group versus the control group.   
While the results of these studies are predominately positive, there are limitations. The 
limitations to these studies include small sample sizes, short duration of follow up, choice of 
primary outcome (should have used knee region such as proximal tibia and distal femur rather 
than hip, lumbar spine or whole body), and inadequate details of the method of 
randomization. In addition, both randomized control trials examined the effects of alendronate 
on BMD in individuals with SCI. Whether etidronate, risedronate, or zoledronic acid has an 
effect on BMD among individuals with chronic SCI is unknown. Consequently, the 
effectiveness of bisphosphonates for the prevention and treatment of osteoporosis among 
individuals with SCI has not been clearly established and needs to be studied further. 




Recently, there have been reports suggesting a relationship between atypical femoral 
fractures (subtrochanteric and femoral shaft fractures) and bisphosphonate use [111]. Lenart 
et al [112] performed a retrospective case-control study of postmenopausal women who 
experienced a low energy femoral fracture from 2000 to 2007 with prolonged bisphosphonate 
use. Bisphosphonate use was reported in 15 of the 41 subtronchanteric and shaft cases 
compared to nine of the 82 intertrochanteric and femoral neck controls. It is unclear whether 
the postmenopausal women in this study had low BMD prior to their fracture because there 
was no information about the degree of osteoporosis prior to their fractures, such as bone 
densitometry values. Therefore, if some of the postmenopausal women had low BMD prior to 
their fracture, their physician may have given them bisphosphonates to improve their bone 
health.  
In another retrospective study [113], radiographs were examined by experts to identify 
features of fractures such as transverse or short oblique fractures, and thick femoral cortices. 
Out of 25 individuals being treated with alendronate, 19 (76%) had radiographic features of 
atypical fractures, while only one out of 45 (2%) had radiographic features of atypical 
fractures in individuals not being treated with alendronate. The risk of sustaining an atypical 
fracture pattern was found to be significantly associated with alendronate use (OR=139, 95% 
CI=19-939, p<0.0001). 
However, the hypothesis that alendronate therapy is associated with atypical fractures 
was not found in a cross-sectional study. Approximately 12 000 Danish people over the age of 
60 years conducted by Abrahamsen et al [114] found that 7% of individuals with atypical 
fractures were alendronate users. A matched cohort study was also performed in the same 
study to test the hypothesis that the increase in risk of atypical femur fractures in individuals 
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treated with alendronate exceeded the increase in ‘typical’ femur fractures caused by 
osteoporosis. The cohort reported a hazard ratio (adjusted for baseline comorbidites) for 
subtrochanteric and femoral shaft fractures with alendronate of 1.46 (0.91-2.35, p=0.12) 
compared with 1.45 (1.21-1.74, p<0.001) for hip fractures. In addition, subtrochanteric and 
femoral shaft fractures were equally common in the alendronate group (14%) and non-
alendronate group (13%) suggesting that an increased risk of atypical fractures with 
alendronate use may be more likely due to osteoporosis than by alendronate therapy.  
The studies to date regarding bisphophonates and atypical fractures include individual 
case reports or case series. No prospective randomized control trials have been conducted, 
therefore it cannot be stated that bisphosphonates cause atypical fractures. Further limitations 
include small sample sizes, narrow inclusion criteria (postmenopausal women; no studies 
have examined atypical fractures among individuals with SCI who are on bisphosphonate 
treatment), lack of radiological and clinical verification, and none of these studies looked at 
the number of individuals who sustained an atypical femoral fracture who have never received 
bisphosphonate therapy. The current research to date on the effect of bisphosphonate use on 
atypical femoral fractures is inconclusive. The studies to date highlight the scope of the 
problem, but they do not provide sufficient evidence that long-term bisphosphonate use is the 
only cause of atypical low-trauma subtrochanteric fractures [115]. More research is needed to 
confirm whether prolonged bisphosphonate use increases the risk of subtrochanteric and 
femoral shaft fractures.  
2.7 Summary of Background 
 
Bone mass significantly declines following a SCI, predisposing individuals with SCI 
to an increased risk of fracture. Analysis of the structure of bone combined with bone density 
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may improve the ability to assess fracture risk in individuals with SCI.  pQCT is a method 
currently being introduced in the SCI population to help predict fracture risk. Examining the 
changes that occur in bone quality among individuals with chronic SCI may facilitate a 
clearer understanding of the risk factors and bone loss contributing to the increased risk of 
fracture. Therefore, the results of our study will inform efforts aimed at identifying 
individuals with SCI who are at greatest risk of fracturing and in need of drug and 
rehabilitation interventions. Furthermore, the findings of this study will increase our 






















3.1 Research Questions 
 
3.1.1 Primary Research Questions 
 
1. Is there a relationship between the indices of bone strength (aBMD, trabecular vBMD 
[mg/cm
3
]; average hole size, HA [mm]; cortical thickness, CTh [mm]; buckling ratio, 
BR; cross-sectional moment of inertia, CSMI [cm
4
]; polar moment of inertia, PMI 
[cm
4
])) and gender, age, bisphosphonate use, time post-injury, completeness of injury, 
or fracture? 
3.1.2 Secondary Research Questions 
 
1. Can the indices of bone strength (aBMD [mg/cm2], trabecular vBMD [mg/cm3]; 
average hole size, HA [mm]; cortical thickness, CTh [mm]; buckling ratio, BR; cross-
sectional moment of inertia, CSMI [cm
4
]; polar moment of inertia, PMI [cm
4
]) in the 
tibia discriminate between individuals with SCI who have sustained a fragility fracture 
of the femur or tibia and those without a history of fractures? Are the indices of bone 
strength correlated with the number of fractures among our sample of individuals with 
chronic SCI?  
2. What proportion of individuals with chronic SCI in each impairment strata (motor 
complete, AIS A and B; motor incomplete, AIS C and D) has a trabecular vBMD at 
the ultra-distal tibia that is below 72mg/cm
3
 [30]?  
3.2 Research Hypothesis 
 




1. It is hypothesized that an inverse relationship will exist between between aBMD, 
trabecular vBMD, cortical thickness, cross-sectional moment of inertia, polar moment 
of inertia and aging and time post-injury. However, it is predicted that a positive 
relationship will exist between average hole size, and buckling ratio and aging, and 
time post-injury. It is hypothesized that bisphosphonate use will positively affect bone 
structure. Bisphosphonate users will have a higher aBMD, trabecular vBMD, cortical 
thickness, cross-sectional moment of inertia, and polar moment of inertia, but a lower 
average hole size and buckling ratio compared to those who are not taking 
bisphosphonates. Furthermore, females, individuals with complete SCI, and 
individuals who have fragility fractures will have lower aBMD, trabecular vBMD, 
cortical thickness, cross-sectional moment of inertia, and polar moment of inertia, but 
a higher average hole size and buckling ratio compared to males, individuals with an 
incomplete SCI, and those with no history of fractures. 
3.2.2 Secondary Research Hypotheses 
 
1. SCI results in partial or complete unloading of the lower limbs. Therefore, it is 
predicted that individuals with chronic SCI who have sustained a fragility fracture will 
possess a lower aBMD, trabecular vBMD, cortical thickness, cross-sectional moment 
of inertia, polar moment of inertia and a larger average hole size compared to those 
with no history of fractures. It is also hypothesized that the buckling ratio will be 
greater among individuals with SCI who have sustained a fragility fracture compared 
to those without any history of fractures. Finally, it is hypothesized that individuals 
with chronic SCI who have sustained multiple fragility fracture will have lower 
aBMD, trabecular vBMD, cortical thickness, cross-sectional moment of inertia, polar 
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moment of inertia and a larger average hole size and buckling ratio compared to those 
with fewer fragility fractures. 
2. It is hypothesized that our sample of individuals with chronic SCI in each impairment 
strata (motor complete, AIS A and B; motor incomplete, AIS C and D) will have a 
trabecular vBMD at the ultra-distal tibia that is below 72mg/cm
3
. Specifically, there 
will be more individuals with a complete SCI (AIS A and B) who have fractured with 
a trabecular vBMD below 72mg/cm
3
 than those with an incomplete SCI (AIS C and 
D) who have fractured. If the first fracture occurs at a trabecular vBMD that is greater 
than 72mg/ cm
3
 then the fracture threshold needs to be moved up; however if the first 
fracture occurs at a trabecular vBMD value that is less than 72mg/cm
3
 then the 
fracture threshold needs to be moved down. 
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4.0 CHAPTER 4: METHODOLOGY 
 
 
4.1 Overview of Study 
 
The present study was a case-control study implemented from a larger 2-year 
prospective study, Bone Quality in Individuals with Spinal Cord Injury. The primary 
objective of the larger prospective study is to establish a cohort of individuals with SCI to 
create the potential for future prospective longitudinal studies evaluating predictors of fracture 
in the SCI population. As a result, guidelines can be developed to identify those at high risk of 
fracture. This study involves collaborations between the University of Waterloo, McMaster 
University, University of Toronto, and the Toronto Rehabilitation Institute, Lyndhurst Centre. 
Eighty individuals with SCI are being recruited to participate in this study, and data being 
collected for the larger prospective study include: a) medical history, including etiology and 
impairment descriptors; b) BMD and body composition assessed by DXA; c) vBMD, bone 
geometry, muscle area and trabecular structure assessed by pQCT; d) x-ray reports to verify 
fractures; and e) serum screening for markers of bone turnover. Figure 4 represents the study 
design and setting for the larger 2-year prospective study. 
The primary focus of this nested case-control study was to examine the baseline data 
to determine whether indices of bone strength (aBMD, trabecular vBMD; average hole size, 
HA; cortical thickness, CTh; buckling ratio; cross-sectional moment of inertia, CSMI; and 
polar moment of inertia, PMI) in the tibia can discriminate between individuals with SCI who 
have sustained a prior low-energy fracture in the tibia and femur compared to those with no 










4.2.1 Study population 
 
A sample of 47 individuals with chronic SCI was recruited over a 21 month period in 
this study. Participants included both genders with a diverse level of impairment, motor 
complete injuries (AIS A and B) and motor incomplete injuries (AIS C and D), which 
established a more representative sample of individuals with SCI. To ensure that participants 
were neurologically and medically stable, and had experienced bone loss that normally occurs 
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one to two years following injury, only individuals who were two or more years post-injury 
were recruited.  
4.2.2 Recruitment and Screening 
 
Participants were recruited through various methods: 1) the Lyndhurst Long-term 
Follow-up Database; 2) Outpatient Services at Lyndhurst Centre; 3) Hamilton Clinic; and 4) 
MacWheelers program at McMaster University. The Lyndhurst Long-term Follow-up 
Database contains the socio-demographic, injury characteristics, health status and contact 
information of SCI individuals who have consented to be contacted regarding ongoing 
research projects at Lyndhurst Centre. Participants that were recruited through the Lyndhurst 
Long-term Follow-up Database or the Hamilton Clinic were sent a letter of invitation 
(Appendix A) to participate in this study. The letter stated that a research coordinator would 
contact them by telephone to determine their eligibility and interest in participating in the 
study. For individuals who preferred not be contacted, a phone number was provided in the 
letter where they could leave a message to opt out of the call.  
Potential participants affiliated with the Outpatient Services at Lyndhurst Centre were 
identified by physicians and therapists. Potential participants’ identified by physicians and 
therapists were informed of their possible eligibility for the study and were asked if they 
would be interested in learning more about the study. The physicians and therapists were 
required to complete referral forms (Appendix A) for eligible participants who expressed 
interest in the study and forward it to the research coordinator who contacted the potential 
participant via telephone. Recruitment through MacWheelers was performed by providing 
brochures to eligible participants. Other recruitment strategies included advertisements on the 
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Canadian Paraplegic Association (CPA) website and newsletter, and posters posted 
throughout the Lyndhurst Centre building. 
Participants interested in partaking in this study were contacted via telephone by the 
research coordinator at Lyndhurst. Potential participants were provided with a detailed 
description of the study. Individuals interested in participating in the study were assessed to 
ensure that they met all the inclusion criteria (Table 5). Eligible participants were arranged a 
visit to Lyndhurst during which a written informed consent was obtained (Appendix A). 
Table 5: Participant Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
 Able to understand instructions in English 
 A spinal cord impairment (C2-T12 AIS 
A-D) of sudden onset (< 24hrs) 
associated with a stable upper motor 
neuron, neurologic deficit of trauma-like 
etiology having occurred at least 24 
months prior study inclusion 
 Ability to give informed consent 
 Age ≥ 18 years 
 Current or prior known conditions other 
than paralysis that are known to influence 
bone metabolism including: oral 
glucocorticoid use for ≥ 3 months, 
malignancy, known liver or malabsorption 
condition 
 Weight > 270lbs (limit for bone density 
machine) 
 Contraindications to pQCT testing 
 Women who are pregnant or planning to 
become pregnant 
 
4.2.3 Assessment Overview 
 
 During the participant’s first visit to Lyndhurst, they were asked a series of question 
pertaining to their medical history and demographics (Appendix A). For example, questions 
regarding current and past medical health, lifestyle behaviours, and medications were of 
interest. The history was obtained by direct patient interview and medical chart review. 
Participants may have also been enquired to undergo an AIS exam if there was no record of a 
previous exam performed. Following the questionnaire and exam, participants underwent a 




 A second visit to the McMaster University Medical Centre was arranged for the 
participant to participate in a pQCT scan. The scans were performed at the ankle (4% site of 
the tibia length) and the widest cross-section of the calf (66% site of the tibia length). The 
scans took approximately 45 minutes. 
4.3 Outcome Measures 
 
4.3.1 Primary Outcome Measures 
 
4.3.1.1 Assessment of Fragility Fractures 
 
Subjects were asked about the time, cause and location of any fragility fractures that 
had occurred after their SCI. Fragility fractures were those that occurred due to low trauma 
(i.e. occurring after falls from standing height or less) in the lower extremity (excluding toes). 
Fractures caused by high-energy trauma and fractures that occurred prior to or at the time of 
SCI were not included in the analysis. Details of prevalent fragility fractures of the lower 
extremity were verified through the participants’ medical records and x-rays, in which a 
written consent was obtained for health record abstraction. Protocols for verifying fractures 
and obtaining records were modelled after those used in CaMOS, a population-based cohort 
study of 10,000 individuals across Canada [116].   
4.3.1.2 Demographics and Medical History 
Past and current medical health, medications, lifestyle and demographic data, and 
information related to the SCI  were obtained via participant interview and chart abstraction, 
and recorded on case report forms and in an electronic database created by EMPOWER Data 
Management and Methods Centre. The Empower database was created to mirror the content 
and format of data collection forms to facilitate ease and accuracy of data entry. Database use 
is restricted to just the investigators of the two year prospective study with logon passwords to 
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the network. SCI history included date of onset, cause, level, and extent of SCI (complete or 
incomplete). A subset of questions from the CaMos medical history questionnaire was 
included to determine variables such as medication use, lifetime tobacco use, and co-
morbidities. The CAGE questionnaire was used as an assessment of alcohol use [117]. 
Medical history, injury information and impairment descriptors was abstracted from the 
patient’s medical record to confirm and supplement information provided by the participant. 
AIS classification for injury level, completeness of injury, and lower extremity motor scores 
in those individuals whose impairment has not been classified was determined by a physiatrist 
using the AIS Classification. 
4.3.2 Secondary Outcome Measures 
 
4.3.2.1 aBMD via DEXA 
 
 DXA scans (Hologic Inc. 4500, MA, USA) were used to obtain areal bone mineral 
density (aBMD, g/cm
2
) measurements at the right distal femur, and right proximal tibia, using 
a standard protocol provided by the manufacturer. In cases of severe spasticity or other 
contraindications, the left leg was scanned instead. Participants reported to the Bone Density 
Lab at Lyndhurst Centre where trained technologists performed the scans. The site is 
equipped with a ceiling lift for transferring patients to the scanning table. The participant was 
positioned supine on the scanning table. Scanning each site took approximately 6 minutes. 
The body needed to be positioned in a specific manner in order to scan the distal femur and 
proximal tibia. Standardizing the position for each regional site reduced aBMD measurement 
errors. The scans were analyzed using commercial available software from Hologic. A lower 
extremity positioning device and protocol, whose reliability and accuracy have been 
previously determined [118] was used to acquire and analyze the scans for the distal femur 
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and proximal tibia. Intra-class correlation coefficients for repeated distal femur and proximal 
tibia BMD measure were 0.99 and 0.97, respectively.  
4.3.2.2 Peripheral Quantitative Computed Tomography 
 
A pQCT scanner (XCT-2000, Stratec Mezintechnik; Pforzheim, Germany) was used 
to scan the tibia. An image is created by reconstructing the 145 projection angles obtained by 
a narrow fan beam emitted from an x-ray tube. The pQCT is a relatively safe technique in that 
the total level of radiation exposure associated during the scans is approximately 1-2μSV, 
which is less than the amount of radiation received with an axial-CT (30-60μSV) or annually 
from background radiation (2500μSV). The right tibia was scanned except in cases of severe 
spasticity or other contraindications, such as the presence of metal or fracture in right leg. 
Bony landmarks at the knee joint and medial malleolus were palpated and a measuring tape 
was used to measure the distance between the two points. The subjects transferred from their 
wheelchair to a height-adjustable chair. The tibia distal endplate (anatomic reference line) was 
identified on a 30mm coronal view of the joint line from a scout scan. The scan site was 
automatically located proximally to this reference line at the following distances: 4% and 66% 
of the tibia length measuring proximally from the distal endplate. Single 2.5mm slices were 
obtained at the ultra-distal tibia (4% of tibia length), and proximal one-third of tibia (66% of 
tibia length). A voxel size of 0.2mm was used at the ultra-distal tibia to have sufficient 
resolution to quantify trabecular structure, while a voxel size of 0.5mm was used at the 
proximal one-third of the tibia. 
 Parameters measured at the 66% site of the tibia included cortical thickness (CTh), 
buckling ratio (BR), cross-sectional moment of inertia (CSMI), and polar moment of inertia 
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(PMI). At the 4% site of the tibia, trabecular vBMD and average hole size (HA) were 
measured.   
Analysis of the scans was performed using the manufacturer’s software (Stratec XCT-
2000 v.6.00) that applies an iterative contour detection algorithm. Contour mode 3 and peel 
mode 2 with an outer threshold of 130mg/mm
3
 and inner threshold of 400mg/mm
3
 was used 
to separate the bone from soft tissue and separate the cortical and subcortical/trabecular bone 
in the image [18]. Contour mode detects the outer bone edge and peel mode defines a method 
in which the subcortical and trabecular bones are separated. Peel mode uses inner thresholds 
to separate the total area into trabecular and subcortical bone, providing information on 
trabecular bone parameters.  
Indices of trabecular bone structure such as average hole size was determined using 
custom developed software. Trabecular architecture was determined by detecting the edge of 
periosteal and endosteal borders by an active contour algorithm. A connectivity analysis was 
performed on the skeletonised trabecular bone segmentation. In addition, a threshold of two 
standard deviations above the soft tissue mean was used to segment the trabecular bone from 
the bone marrow. The long- and short-term precision for this technique has been reported 
elsewhere [119]. 
4.4 Indices of Bone Strength 
 
4.4.1 Areal Bone Mineral Density 
 
 Areal BMD determined by DXA is the current gold standard in assessing 
osteoporosis. Areal BMD measurements of the distal femur and proximal tibia were acquired 







account for small changes in bone density and be able to interpret the results in a clinical 
manner. 
      
   
    
 
 
4.4.2 Trabecular vBMD 
 
A unique feature that is providing the pQCT with more attention is its ability to 
measure volumetric bone mineral densities (vBMD, mg/cm
3
). Individuals with chronic SCI 
experience a substantial reduction in trabecular vBMD in the femur and tibia [19], which has 
been reported to be the best parameter in determining fracture threshold [30]. 
     
    
      
 
   
      
 
 
4.4.3 Average Hole Size 
 
 Average hole size was defined as the average area of each hole (concealed around by 
bone) in the distal femur and proximal tibia. 
4.4.4 Cortical Thickness  
 
Cortical thickness of the tibia was assessed assuming the circular ring model derived 
by pQCT-based measurements. The circular ring model assumes that the shape of the 
measured object is a circular ring and estimates cortical thickness by calculating the 
difference between the outer and inner radius. 
         
      
   
 
      
   
 
 
4.4.5 Cross-sectional Moment of Inertia 
 
 Cross-sectional moment of inertia is an estimation of the resistance of bone to 
bending. It is a function of the cross-sectional area of a voxel (A) and the mean y-coordinate 
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for all voxels of the cortical area (YCRTAy). Bone distributed further from the axis of rotation, 
leads to larger resistance to bending. Cross-sectional moment of inertia units will be 
converted to cm
4
 to account for large changes and be able to interpret the results in a clinical 
manner. 
                 
  
4.4.6 Polar Moment of Inertia 
 
 Polar moment of inertia represents the ability of bone to resist bending. Polar moment 
of inertia takes into account the distance of the voxel (d) from the center of gravity (C) and 
the cross-sectional area of a voxel (A, in this study it is 0.5mm x 0.5mm = 0.25mm
4
) (Figure 
5) [120,121].  The units for polar moment of inertia will be converted to cm
4
 to account for 
large changes and be able to interpret it in a clinical manner. 
                           
 
         
   
Figure 5: Calculation of Polar Moment of Inertia in the Tibia  
4.4.7 Buckling Ratio 
 
Bucking ratio expresses the likelihood of failure in bending due to excessive cortical 
thinning. Higher values would suggest a greater instability due to thin-walls that may 
contribute to fractures.  
Buckling ratio was calculated using the following formula: 
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Peak bone mass is the maximum BMD achieved and has been shown to be a 
significant predictor of BMD later in life. BMD is accumulated throughout childhood into 
adolescence until peak bone mass is achieved between the ages of 20 and 25 years. Peak bone 
mass generally occurs much earlier in girls than in boys [122]. Peak bone mass is sustained 
until around 30 to 40 years of age, at which then they experience an average 1% per year 
decline in BMD with aging [123]. The decline in BMD can accelerate to 2% per year with the 
onset of menopause [124]. Therefore, the risk of osteoporotic fractures in later life may be the 
result of peak bone mass achieved during skeletal maturity and age-related bone loss.  
Age was represented as mean±SD for descriptive analysis and was represented as a 
continuous variable for the regression model. 
4.5.2 Gender 
 
Gender has been reported to be a significant predictor of BMD. On average, men have 
larger bones and higher peak bone masses than women. Boys and girls acquire bone mass at 
similar rates before puberty; however after puberty, men generally acquire more bone mass 
than women [122]. 
After menopause, bone loss is accelerated in women because of a rapid decline in 
estrogen levels, resulting in an increase in bone turnover, which is dominated by an increase 
in bone resorption. During menopause, the levels of bone resorption markers are two times 
higher than in premenopausal women, whereas the bone formation markers are only 
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approximately a half higher than premenopausal levels [125]. Accordingly, a negative balance 
in bone remodelling occurs.  
Among individuals with SCI, Garland et al [1] reported women lose more bone at all 
skeletal sites below the level of the lesion compared to men. 
Gender was represented as a dichotomous variable in the regression models. 
4.5.3 Time post Injury 
 
A relationship between indices of bone strength and time post-injury/duration of injury 
is plausible among individuals with SCI as time post-injury has been suggested as a indicator 
of fracture risk in studies comparing individuals who have a history of fractures to those who 
do not [6,14]. Furthermore, time post injury may be an alternative method for measuring the 
changes that occur in cortical bone which occurs later than the changes that occur in 
trabecular bone.  Cortical bone has a slower turnover rate compared to trabecular bone [126].  
Therefore, time post injury may explain the rate of bone turnover for both cortical and 
trabecular bone.  
Duration of injury was calculated as the date of injury minus the date of demographics 
and medical history assessment. Duration of injury was measured in years and represented as 
a continuous variable in the regression model. 
4.5.4 Completeness of Injury 
 Completeness of injury has been shown to take precedence over most modifiable and 
non-modifiable factors for bone loss at the distal femur and proximal tibia leading to 
pathological fractures in a cross-sectional study of 152 individuals with chronic SCI.  
Individuals with a complete SCI were reported to be 6.17 times more likely to have an aBMD 
of the knee low enough to be a member of the osteoporotic category [87]. 
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 Motor completeness of injury was represented as a dichotomous variable (complete, 
AIS A and B versus incomplete, AIS C and D) for the regression models. 
4.5.5 Bisphosphonate Use 
 
 Data from two randomized control trials suggest that the oral bisphosphonate, 
alendronate, may help in maintaining BMD in the lower extremities among individuals with 
SCI [109,110]. In another double-blinded, randomized, placebo-controlled trial, in 17 
individuals with acute SCI, administration of 4 or 5mg of intravenous zoledronic acid was 
reported to increase section modulus at the intertrochanteric regions and decrease buckling 
ratio after 12 months in the proximal femur [127]. However, the effect of bisphosphonates on 
the structure of bone in individuals with chronic SCI has not been determined.  
 Current bisphosphonate users were represented as a dichotomous variable (users 
versus non-users) in the regression model. 
4.5.6 Fragility Fractures 
 
 Previous fracture(s) is an important risk factor for future fractures in men and women 
[17,128]. In postmenopausal women, fractures were reported to most commonly occurred in 
women with a previous osteoporosis-related fracture (OR=3.3, 95% CI=1.75-5.66) [129].  
Unfortunately, the effect of prior fragility fractures on individuals with SCI has not been 
examined. 
 The presence of fragility fractures were represented as a dichotomous variable 
(individuals with fractures, =1 versus those with no fractures, =0) in the regression model.  
4.6 Statistical Analysis 
 
Descriptive statistics were used to summarize anthropometric measurements of the 
study population and each index of bone strength (aBMD, trabecular vBMD; average hole 
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size, HA; cortical thickness, CTh; buckling ratio, BR; cross-sectional moment of inertia, 
CSMI; polar moment of inertia, PMI). Descriptive statistics were also used to characterize the 
proportion of individuals that had a fracture, the skeletal sites of the fractures, and the cause 
of the fractures. Dichotomous variables were presented as counts (n) and percentage (%) and 
continuous variables were presented as means ± standard deviations (SD). Two-sided t-tests 
and Chi-Square test were used to make the comparison between individuals with SCI with 
and without fractures.  
 Linear regression analysis was performed to determine whether the indices of bone 
strength (aBMD, trabecular vBMD; average hole size, HA; cortical thickness, CTh; buckling 
ratio, BR; cross-sectional moment of inertia, CSMI; polar moment of inertia, PMI) were 
associated with gender, age, bisphosphonates, time post injury, completeness of injury, and 
fracture among our sample of individuals with SCI. Correlates found to be statistically 
significant at alpha=0.20 in linear regression were entered into multivariable linear regression 
models to identify correlates of each of the indices of bone strength. To assess model 
assumptions, the residuals were examined.  
The relative risk of a fragility fracture was estimated by odds ratio (OR) and 95% 
confidence intervals (CI) obtained from logistic regression where the presence of a fragility 
fracture was the dependent variable and the indices of bone strength (aBMD, trabecular 
vBMD; average hole size, HA; cortical thickness, CTh; buckling ratio, BR; cross-sectional 
moment of inertia, CSMI; polar moment of inertia, PMI) were the potential correlates. Models 
were adjusted for any risk factors that were significant correlates of indices of bone strength 
in a secondary analysis. Further analysis with Poisson regression occurred to model the 
number of fractures per participant as a function of the indices of bone strength (aBMD, 
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trabecular vBMD; average hole size, HA; cortical thickness, CTh; buckling ratio, BR; cross-
sectional moment of inertia, CSMI; polar moment of inertia, PMI).  
Proportions were calculated to report the number of individuals with chronic SCI in 
each impairment strata (motor complete, AIS A and B; motor incomplete, AIS C and D) that 
had a trabecular vBMD at the ultra-distal tibia that was below 72mg/cm
3
. 
All statistical analysis was performed on SAS 9.2 software (Cary, North Carolina), in 
which all statistical tests were two-sided. The criterion for statistical significance was set at 
alpha = 0.05. The proportion of variance from a linear regression was determined by 
interpreting the regression coefficients (R
2
). Correlation coefficient (r) from regression 
models were interpreted as follows: ≤0.29=very weak, 0.30-0.49=weak, 0.50-0.69=moderate, 
0.70-0.89=strong, and ≥0.90=very strong [130].  
4.7 Ethical Considerations 
 
4.7.1 Potential Risks to the Participants 
 
Participants were exposed to small amounts of radiation during the DXA and pQCT 
scans. The total level of radiation exposure associated with the scans is approximately 30µSv, 
which is less than the amount of radiation received during an axial CT scan (30-60µSv) or 
annually from background radiation (2500µSv). 
4.7.2 Anonymity 
 
Each participant was assigned a unique identification (ID) number that was used on all 
forms and in the electronic database. The key file linking participant information to the ID 
was stored in a separate password protected database. All hardcopy data was stored at the 
Research Department at Toronto Rehabilitation Institute, Lyndhurst Centre in lockable and 
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secured filing cabinets. A compilation of all the research data was inputted and securely 
stored on an online electronic database, Empower, on the servers at Lyndhurst Centre. 
4.7.3 Ethics 
 
Ethical approval for this study was obtained from the Ethics Review Boards of 





















5.0 CHAPTER 5: RESULTS 
 
 
5.1 Recruitment and Sample Size 
 
Two hundred and eight nine individuals with SCI were approached for the larger two 
year prospective study, Bone Quality in Individuals with chronic SCI. Of the 289 individuals, 
157 individuals were unreachable by phone, seven were deceased, and 57 had declined to 
participate, resulting in 68 individuals to be pre-screened for eligibility. Four individuals did 
not meet the inclusion criteria and 13 individuals declined further participation in the study. 
Of the 51 individuals who met the eligibility criteria, three were pending baseline assessment 
completion and one was deceased, leaving 47 individuals with chronic spinal cord injury to be 
included in this study (Figure 6). 
 DXA scans could not be performed at the distal femur in five participants, three 
because of hardware located in both femurs, and the other two because of bilateral fractures of 
the knee. In addition, DXA scans for both the proximal tibia and distal femur could not be 
performed in one participant due to hardware located in the both knee regions. As a result, 
measurements of aBMD at the distal femur and proximal tibia obtained by DXA were 
performed on 41 and 46 individuals with SCI, respectively. pQCT scans could not be 
performed at both the ultra-distal tibia (4% site) and the proximal one-third of the tibia (66% 
site) in three participants; one individual experienced spasms, which could lead to movement 
artefacts and prevent safe scanning; one participant had died and one declined to participate in 
the pQCT scan. Furthermore, two additional pQCT scans could not be performed at the 66% 
site because the participants’ calves were too large to fit in the gantry. Four individuals’ 
pQCT scans were still pending at the time of analysis and one individual was not able to 
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travel to Hamilton within the three month window period for baseline completion. Therefore, 
39 individuals were scanned at the 4% site and 37 individuals were scanned at the 66% site.   
Figure 6: Flow chart of cohort refinement 
5.2 Participant Characteristics 
 
5.2.1 Sociodemographics and Impairment 
 
The sample population consisted of 47 individuals with SCI; 33 males (70.2%) and 14 
females (29.8%) (Table 6). The participants’ age ranged from 32 to 77 years, with a mean age 
of 51.1±11.4 years. The mean time post injury was 15.9±10.2 years which ranged from 2 to 
41 years. Twenty nine individuals with SCI were reported to have a motor complete SCI (AIS 
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A and B), in which 12 were tetraplegics and 17 were paraplegics. Eighteen individuals were 
classified as motor incomplete (AIS C and D); 11 tetraplegics and seven paraplegics. All of 
the SCI were of traumatic etiology. The majority of SCI occurred as a result of MVA (n=24), 
followed by falls (n=10), sports-related (n=8), work-related (n=3), others (n=2), and violence 
(n=1) (Table 7). One individual sustained two spinal cord injuries; one sports related and one 
work-related. 
Table 6: Sociodemographic and Impairment Characteristics 











No Subjects, n (%) 47 14 (29.8%) 33 (70.2%)  
Sex, n (%)    0.905 
     Male 33 (70.2%) 10 (71.4%) 23 (69.7%)  
     Female 14 (29.8%) 4 (28.6%) 10 (30.3%)  
Age (years) 51.1±11.4 51.8±9.93 50.8±12.1 0.794 
Duration of injury (years) 15.9±10.2 22.6±10.9 13±8.5 0.002
* 
Height (cm) 174.3±9.7 174.8±11.7 174.1±8.9 0.897 
Weight (kg) 80.9±19.8 81.2±21.4 80.8±19.4 0.954 
Waist Circumference (cm)
†
 97.9±14.9 101.0±17.4 96.7±13.9 0.387 
Injury Characteristic, n (%)    0.033
* 
    Motor Complete Paraplegia 17 (36.2%) 8 (57.1%) 9 (27.3%)  
    Motor Incomplete Paraplegia 7 (14.9%) 1 (7.1%) 6 (18.2%)  
    Motor Complete Tetraplegia 12 (25.5%) 5 (35.7%) 7 (21.2%)  
    Motor Incomplete Tetraplegia 11 (23.4%) 0 (0.0%) 11 (33.3%)  
AIS, n (%)    0.017
* 
    A 28 (59.6%) 12 (85.7%) 16 (48.5%)  
    B 1 (2.1%) 1 (7.1%) 0 (0.0%)  
    C 7 (14.9%) 1 (7.1%) 6 (18.1%)  
    D 11 (23.4%) 0 (0.0%) 11 (33.3%)  
LEMS
‡




 101.3±54.9 93.8±55.7 104.4±55.1 0.562 
†Indicates n=46 
‡Indicates n=45 due to incomplete data 
*Significant difference between fracture and non-fractured group (Student’s t-test p value 




Table 7: Cause of the Spinal Cord Injuries 
Cause of SCI Number of Subjects 
(n=47) 
MVA 24 (51.0%) 
Falls 10 (21.3%) 
Violence 1 (2.1%) 
Sports 8 (17.0%) 
Work-related 3 (6.4%) 
Other 2 (4.3%) 
Note: one participant had two spinal cord injuries (one sports and one work-related) 
 
5.2.2 Supplement Intake 
 
 The use of supplements was generally high, with 86.9% (n=40) of the cohort reporting 
the use of a calcium supplement, 89.7% (n=42) reporting the use of vitamin D, and 58.1% 
(n=25) reporting the use of a multivitamin. 
At the time of assessment, twenty-seven participants (58.7%) were on bisphosphonate 
therapy for prevention and treatment of osteoporosis: etidronate (n=1, 2.1%), risedronate 
(n=6, 12.8%), alendronate (n=14, 29.8%), and alendronate with vitamin D (fosavance, n=6, 
12.8%) (Table 8). 
Table 8: Supplement Intake 






Bisphosponate User, n (%)    
     Etidronate 1 (2.1%) 1 (7.1%) 0 (0.0%) 
     Risedronate 6 (12.8) 1 (7.1%) 5 (15.1%) 
     Alendronate 14 (29.8%) 5 (35.7%) 9 (27.3%) 
     Fosavance 6 (12.8%) 3 (21.4%) 3 (9.1%) 
Calcium Supplement, n (%) 40 (86.9%) 14 (100%) 26 (81.3%) 
Vitamin D Supplement, n (%) 42 (89.7%) 14 (100%) 28 (84.8%) 






5.2.3 Lifestyle Behaviours 
 
 There were eleven smokers (23.4%) in the cohort. Sixty eight percent of the 
participants were prior smokers (n=32), with a mean of 13 cigarettes per day, while 15 
participants had never smoked. The cohort also reported alcohol intakes ranging from 0 to 14 
drinks per week; twenty four individuals were current drinkers (one or more drinks per week), 
while 31 individuals reported having a history of alcohol intake (Table 9).  
Table 9: Lifestyle Behaviours 






No Subjects, n (%) 47 14 (29.8%) 33 (70.2%) 
Smoking, n (%)    
     Never 15 (31.9%) 4 (28.6%) 11 (33.3%) 
     Current Smoker 13 (23.4%) 3 (21.4%) 10 (30.3%) 
     Previous Smoker 32 (68.1%) 10 (71.4%) 22 (66.6%) 
Alcohol consumption, n (%)    
     Current Alcohol 24 (51.1%) 8 (57.1%) 16 (48.5%) 
     History of Alcohol 31 (66.0%) 13 (92.9%) 18 (54.5%) 
 
5.3 Fragility Fractures 
 
 Thirty percent of participants (n=14) had a sustained a fragility fracture following their 
SCI in which eight participants had sustained multiple fragility fractures (range 2-7 fractures) 
after their SCI. Ten were males (71.4%) and four were females (28.6%). Fragility fractures 
occurred as a result of torsion (n=5), low velocity falls (n=17), transfers (n=11), and other 
methods (n=3) such as during intercourse, by spasms, and being hit in the leg (Table 10). 
Lower extremity fragility fractures occurred more frequently at the femur (n=14) followed by 
the tibia (n=11), ankle (n=5), knee (n=3), and fibula (n=2) (Figure 7). One individual reported 
three fractures in the knee because he/she was unsure where exactly around the knee 
(proximal femur, distal tibia, or patella) the fracture had occurred.  
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Table 10: Causes of Fragility Fractures 
Cause of Fragility 
Fracture 






Torsion 5 4 1 
Low Velocity Fall 17 15 2 
ROM 0 0 0 
Hyperflexion 0 0 0 
Transfer 11 3 8 
Other 3 1 2 
TOTAL 36 23 13 
 
Figure 7: Location of lower extremity fragility fractures 
5.4 Indices of Bone Strength 
 
Table 11 summarizes the indices of bone strength for all subjects, those who have a 
history of fragility fractures and those who did not. Trabecular vBMD (p=0.0006), cortical 
thickness (p=0.0137), cross-sectional moment of inertia (p=0.0027), polar moment of inertia 
(p=0.0149), and aBMD at the distal femur (p=0.0004) and proximal tibia (p=0.0006) were 





























Location of Fragility Fracture
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those who had not. In addition, those who had fractured had a significantly higher average 
hole size (p=0.0007) compared to non-fractured subjects. 
Table 11: Comparison of Indices of Bone Strength between those with a History of 

























) 12.6±20.0 30.2±30.6 6.6±9.6 0.0007
* 
66% CTh (mm) 3.3±0.9 2.7±0.7 3.5±0.9 0.0137
* 
 BR 5.2±1.8 6.1±2.0 4.9±1.7 0.0886 
 CSMI (cm
4




) 4.3±1.7 3.2±0.9 4.7±1.8 0.0149
* 












488.7±163.6 360.9±102.9 544.6±153.6 0.0006
* 
*Significant difference between fractures and non-fractured subjects (p<0.05) 
 
5.5 Identifying Risk Factors Related to Indices of Bone Strength 
 
Completeness of injury, bisphosphonate use, and fractures were correlates of aBMD in 
the distal femur (R
2
=0.5692, Table 12). Completeness of injury, duration of injury, and 
bisphophosphonate use were correlates of proximal tibia aBMD (R
2
=0.6075). Duration of 
injury and completeness of injury were found to be correlates of trabecular vBMD 
(R
2
=0.4518), while duration of injury and fractures were correlates of average hole size at the 
ultradistal tibia (R
2
=0.4290). Duration of injury was found to be the sole correlate of cortical 
thickness (R
2
=0.2133) and buckling ratio (R
2
=0.1634).  Finally, gender, completeness, 





=0.5751), while these risk factors with the exception of fractures were found to be 





Table 12: Risk Factors Associated with Indices of Bone Strength 


























Subjects, n 41 46 39 39 37 37 37 37 
Gender − − − − NS − Significant Significant 
Age NS − − − − − − − 
Duration of Injury NS Significant Significant Significant Significant Significant NS NS 
Completeness of 
Injury 
Significant Significant Significant NS NS NS Significant Significant 
Bisphosphonate Use Significant Significant NS NS NS - Significant Significant 
Fractures Significant NS NS Significant NS NS Significant NS 
P-Value for Model <0.0001 <0.0001 <0.0001 <0.0001 0.0040 0.0131 <0.0001 <0.0001 
R-Square for Model 0.5692 0.6075 0.4518 0.4290 0.2133 0.1634 0.5751 0.5149 
− =not significant in linear regression models (p>0.2); NS=not significant in multiple linear regression models (p>0.05) 
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5.6 Fractures and Indices of Bone Strength 
 
 Logistic regression was performed to identify the indices of bone strength associated 
with having at least one fragility fracture. Unadjusted and adjusted odds ratio (OR), 95% 
confidence intervals (CI), and p-values are reported in Table 13. When a univariate analysis 
was performed, all of the indices of bone strength except for buckling ratio were associated 
with fragility fractures. However, after adjusting for the correlates associated with the indices 
of bone strength, we only found aBMD at the distal femur, average hole size, and cross-
sectional moment of inertia were significantly associated with fractures. Individuals with 
chronic SCI who have a higher average hole size in the ultra-distal tibia (OR=1.081, 95% 
CI=1.001-1.166, p=0.0470) and lower cross-sectional moment of inertia (OR=0.098, 
95%CI=0.012-0.838, p=0.0338) are at increased odds of experiencing a fragility fracture. In 
addition, individuals with SCI with higher aBMD at the distal femur were at decreased odds 
of fracturing (OR=0.988, 95% CI=0.978-0.998, p=0.0226). Each one SD (0.1mg/cm
2
) 
increase in aBMD at the distal femur was associated with 1.2% decrease in fragility fractures 
after adjusting for completeness of injury and bisphosphonate use. We attempted to put 
aBMD at the distal femur and average hole size, and aBMD at the distal femur and cross-
sectional moment of inertia into a multivariable logistic regression model to determine if 
average hole size or cross-sectional moment of inertia improves the ability of aBMD at the 
distal femur to differentiate between individuals with SCI with fractures and those without. 
We found that average hole size and cross-sectional moment of inertia did not explain any 
additional variance. We found that pQCT measures of average hole size (aBMD: OR=0.989, 
95% CI=0.977-1.000, p=0.0584; HA: OR= 1.020, 95% CI=0.966-1.078, p=0.4692) and cross-
sectional moment of inertia (aBMD: OR=0.989, 95% CI=0.976-1.002, p=0.1022; CSMI: 
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OR=0.131, 95%CI=0.011-1.519, p=0.1041) did not improve fracture correlations over aBMD 
at the distal femur alone.  However, aBMD at the distal femur was found to be moderately 
negatively correlated with average hole size (r=-0.5038, p=0.0011, Figure 8) and moderately 
positively correlated with cross-sectional moment of inertia (r=0.6918, p<0.0001, Figure 9).  
Based on the poisson regression model, the bone strength variables were significantly 
correlated with the number of fragility fractures sustained (Table 14).  Adjusting for risk 
factors related to the bone strength variables did not alter the regression models predicting the 
number of fractures and therefore were not included in the final analysis. The expected 
change in log count for a one unit increase in cross-sectional moment of inertia and buckling 
ratio were -1.1456 and 0.2030, respectively. In other words, individuals with SCI with a 
higher cross-sectional moment of inertia will have 68.2% [1-exp (-1.1456)] fewer fragility 
fractures than individuals with SCI with lower cross-sectional moment of inertia. In addition, 
individuals with SCI with a higher buckling ratio will have 23% [exp (0.2030)] more fragility 
fractures than individuals with SCI with a lower buckling ratio.  
The results examining the relationship between bone strength variables and fragility 
fractures were based on pQCT scans with and without movement artefacts. Therefore, a 
sensitivity analysis was performed to determine whether excluding the scans with movement 
artefacts would affect the results obtained from the odds ratio and poisson regression 
(Appendix B). We found that aBMD at the distal femur and cross-sectional moment of inertia 
remained significant while average hole size became insignificant (OR=1.082, 95% CI= 
0.999-1.172, p=0.0521). In addition, aBMD at the proximal tibia (OR=0.985 95% CI=0.971-
0.998, p=0.0278) and polar moment of inertia (OR=0.346 95% CI=0.122-0.983, p=0.0463) 
became significant. With regards to the poisson analysis, all of the indices of bone strength, 
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aBMD at the distal femur (mg/cm2)
except for buckling ratio (p=0.0957) remained significantly correlated with the number of 
fragility fractures. 
Figure 8: Relationship between average hole size at the ultra-distal tibia and aBMD at 
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Note: When outlier (918, 5.017) was removed r=0.674 
71 
 
Table 13: Adjusted Odds Ratio and 95% Confidence Intervals for Indices of Bone Strength Associated with Fragility Fracture 
 Fractures (Unadjusted) Fractures (Adjusted) 





) 0.989 (0.981-0.997) 0.0090
*




) 0.987 (0.979-0.996) 0.0035
*
 0.989 (0.978-1.000) 0.0535 
vBMD (mg/cm
3
) 0.963 (0.937-0.990) 0.0084
*
 0.971 (0.937-1.005) 0.0931 
HA (mm
2
) 1.089 (1.013-1.170) 0.0216
*
 1.081 (1.001-1.166) 0.0470
* 
CTh (mm) 0.327 (0.124-0.859) 0.0234
*
 0.453 (0.162-1.263) 0.1300 
BR 1.387 (0.933-2.060) 0.1056 1.175 (0.766-1.803) 0.4609 
CSMI (cm
4






) 0.422 (0.196-0.908) 0.0274
* 
0.419 (0.170-1.031) 0.0584 
Notes: CI = confidence interval; OR = odds ratio; DF = distal femur; PT = proximal tibia  
†adjusted for correlates of bone strength variables: aBMD at the distal femur and proximal tibia were adjusted for completeness of 
injury and bisphosphonate use; trabecular vBMD was adjusted for duration of injury and completeness of injury; HA, CTh, and BR 
were adjusted for duration of injury; CSMI and PMI were adjusted for gender, completeness of injury, and bisphosphonate use.  
*Statistically significant at alpha=0.05 
 
Table 14: Indices of Bone Strength Associated with the Number of Fragility Fractures Sustained 
 Change in log count Upper 95% CI Lower 95% CI p-value 
aBMD-DF (mg/cm
2












) 0.0237 0.0150 0.0324 <0.0001
* 
CTh (mm) -0.6835 -1.1252 -0.2418 0.0024
* 








) -0.5848 -0.9421 -0.2275 0.0013
* 
Notes: CI = confidence interval; DF = distal femur; PT = proximal tibia;  
*Statistically significant at alpha=0.05 
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5.7 Fracture Threshold and Fracture Breaking Point 
 
Based on SCI-specific fracture thresholds (≤0.78g/cm
2
) and fracture breaking point 
(≤0.49g/cm
2
) at the distal femur obtained by Garland et al [29], approximately 78% and 39% 
of individuals with SCI were at risk of fracture, respectively. A larger proportion of 
individuals with motor complete SCI compared to individuals with motor incomplete SCI had 
a fracture threshold of less than or equal to 0.78g/cm
2
 (72% versus 28%) and a fracture 
breaking point of less than or equal to 0.49g/cm
2
 (88% versus 13%). Based on Eser et al’s 
[30] trabecular vBMD fracture threshold in the tibia (<72mg/cm
3
), 7.7% (three out of 39) of 
individuals with chronic SCI were at risk of fracture in which 100% of individuals had motor 
complete injuries (Table 15).  
All of the subjects who had sustained a fragility fracture had trabecular vBMD in the 
tibia of less than or equal to 126mg/cm
3
 (Figure 10). One individual with seven fragility 
fractures had a trabecular vBMD of 66.1mg/cm
3
. Individuals with chronic SCI who had never 
















Table 15: Proportion of Individuals with Chronic SCI who are Below Previously 
Defined Fracture Thresholds 















All Subjects, n (%) 41 39 41 
     AIS A-B 23 (56.1%) 3 (7.7%)
 
14 (34.2%) 
     AIS C-D 9 (22.0%) 0 (0.0%)
 
2 (4.9%) 
Subjects with one Fragility Fracture, n (%) 5 5 5 
     AIS A-B 4 (80.0%) 0 (0.0%) 3 (60.0%) 
     AIS C-D 1 (20.0%) 0 (0.0%) 1 (20.0%) 
Subjects with Multiple Fractures, n (%) 5 5 5 
     AIS A-B 4 (80.0%) 2 (40.0%) 4 (80.0%) 
     AIS C-D 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 
Figure 10: Trabecular vBMD of the Distal Epiphysis of the Tibia versus Time after 
Injury 
 
Legend: ♦, subjects who had never had a fracture; ■, subjects who had 1 fracture; ▲, 
subjects who had multiple fractures; upper dashed line represents the highest trabecular 







































To our knowledge, this is the first study to examine the relationships between indices 
of bone strength obtained by pQCT and fragility fractures in the lower extremity in men and 
women with chronic SCI. Most studies on bone loss in individuals with SCI focus on changes 
in bone density employed by DXA. In this study, we found that the presence of specific risk 
factors, namely duration of injury, completeness of injury, bisphosphonate use, fractures, and 
gender are potential correlates of DXA and pQCT-based bone strength measures. In addition, 
individuals with SCI with fractures had significantly lower indices of bone strength than those 
without fractures. Our preliminary data found that individuals who had lower aBMD at the 
distal femur, larger average hole sizes, or lower cross-sectional moment of inertia may be at 
increased risk of sustaining at least one fragility fracture in the lower extremity. Furthermore, 
we found that each of the bone strength variables were significantly correlated with the 
number of fragility fractures sustained. Finally, we found a trabecular vBMD fracture 
breaking point of approximately 126mg/cm
3
 at the distal tibia. 
6.2 Risk Factors Associated with Indices of Bone Strength 
 
In the able bodied population, female gender, age, fracture history, glucocorticoid use 
and T-score for the femoral neck are the major risk factors that contribute to osteoporotic 
fractures. However, other clinical factors that contribute to fractures as a result of low BMD 
include current smoker, high alcohol intake, low body weight, disorders associated with 
osteoporosis, rheumatoid arthritis, parental history of fractures, prolonged glucocorticoid use, 
and prior fragility fractures [17,131,132]. Applying these risk factors to assess fracture risk in 
individuals with SCI may not be appropriate as bone loss is distinct from that seen in the able-
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bodied population with respect to rate of onset, severity of decline in aBMD and bone 
architecture [66,133], etiology [66], and location of fracture risk [134].  
In the present study, the risk factors associated with the indices of bone strength in 
individuals with SCI are completeness of injury, bisphosphonate use, fractures, duration of 
injury, and gender. Completeness of injury, bisphosphonate use, and fractures were the 
overriding risk factors for low aBMD in the distal femur, while duration of injury, 
completeness of injury, and bisphosphonate use were correlates of aBMD at the proximal 
tibia among individuals with SCI. In fact, these risk factors contribute to more than half of the 
possible reasons as to why individuals with SCI may be experiencing low aBMD in the knee. 
Completeness of injury has been previously determined to have a very strong influence on 
low BMD, suggesting that individuals with complete injuries are more than 6 times more 
likely to have BMD of the knee low enough to place them into the osteoporotic category [87]. 
Individuals with incomplete injuries have the ability to contract their muscles, and possibly 
weight bear which may account for the higher BMD compared to individuals with motor 
complete injuries.  
Our findings also suggest that bisphosphonate use may be an important correlate of 
aBMD; however, there is minimal evidence currently available in the literature that suggests 
bisphosponate use can be used for the prevention and treatment of BMD loss following a SCI 
[135]. Administration of 10mg daily oral alendronate plus elemental calcium to a group of 
individuals with chronic and acute SCI for a period of 24 months showed statistically 
significant (p=0.017) treatment effect (-2.0±2.9%) compared with the control group who were 
only being administered elemental calcium (-10.8±2.7%). BMD remained stable in the distal 
tibia epiphysis and total hip in the alendronate group compared to the control group [109]. 
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Another study found no variation in BMD values in the lower extremity in the treatment 
group (0.01±0.02%) relative to the control group (-0.01±0.05%) following a six month 
intervention [110]. A major limitation to the above randomized controlled studies is that they 
did not examine the role of alendronate on fracture-prone SCI sites such as the distal femur 
and proximal tibia. In addition, these studies only looked at the bisphosphonate alendronate. 
Our study found that bisphosphonate use, whether it be on alendronate, etidonate, fosavance, 
or risedronate, was associated with aBMD at the distal femur and proximal tibia.  With 
respect to the able-bodied population, there is good evidence that alendronate, etidronate, and 
risedronate prevent vertebral fractures, nonvertebral fractures and hip fractures more than the 
placebo group [136]. A study in which women were assigned to either placebo or 5mg daily 
of alendronate for two years followed by 10mg daily of alendronate for another two years 
found that individuals assigned to the alendronate group had statistically higher BMD 
(p<0.001) in the total hip, lumbar spine, and femoral neck compared with the placebo group. 
Alendronate also significantly reduced the risk of clinical fractures by 36% in women whose 
initial femoral neck T-score was -2.5 or less (RH=0.64, 95% CI=0.50-0.82), but four years of 
alendronate did not affect the risk of clinical fractures in those with an initial T-score greater 
than -2.5 (RH=1.08, 95% CI=0.87-1.35) [137]. Based on our results and previous work, 
bisphosphonate treatment is important to maintain and/or improve bone density among 
individuals with SCI.  
 Duration of injury was also found to be a strong correlate of bone strength variables. It 
was significantly associated with all of the bone strength variables, expect for aBMD at the 
distal femur, cross-sectional moment of inertia and polar moment of inertia. Using a multiple 
linear regression model with age, BMI, and duration of injury, Garland et al found a similar 
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relationship in which duration of injury was not associated with aBMD at the knee, but the 
association did approach significance (p=0.07) [138]. The reason for why duration of injury 
was a correlate of aBMD at the proximal tibia and not aBMD at the distal tibia could be due 
to skeletal heterogeneity of the sample population. In a monozygotic twin study, Bauman et al 
[94] found a negative association between bone density and duration of injury such that twins 
with SCI lost BMD in the leg over approximately three decades in amounts proportional to 
duration of injury. However, this study performed a single linear regression analysis 
examining the direct relationship between aBMD at the knee and duration of injury. Our study 
is unique in that we performed a multiple linear regression analysis examining the effects of 
many different potential correlates of losses in bone density at the knee. Initially, we 
performed a linear regression model that did not adjust for completeness of injury, 
bisphosphonate use, or fractures, and found that duration of injury was associated with aBMD 
at the distal femur (p=0.0040). This is line with previous studies which found a direct 
relationship between duration of injury and aBMD at the knee [6,20]. Therefore, our study 
supports the idea that duration of injury is an important correlate of bone strength variables.  
Our study also found that gender is an important correlate of cross-sectional moment 
of inertia and polar moment of inertia. Cross-sectional moment of inertia and polar moment of 
inertia are a function of bone’s distribution from the axis of rotation; the wider the bone, the 
more resistance it has to torsion or bending. During growth, boys generally obtain wider 
bones with a thicker cortex, while women obtained more thinner narrow bones [45]. As a 
result, females are a higher risk of fracturing compared to males. There was no evidence that 
gender or age of the participant were significant confounders for any of the other indices of 
bone strength assessed. Previous studies have reported that gender [87] and age [14,96,138] 
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are not significantly associated with BMD of the knee in individuals with SCI, while one 
previous study did find an association between age and BMD z-score at the knee [87]. In the 
able-bodied population, female gender and age are the most important predictors for 
osteoporosis [132,139]. Post-menopausal women and men over the age of 50 are at higher 
risk of osteoporosis and subsequent fractures [17]. Gender and age were not found to be a risk 
factor associated with aBMD perhaps because the number of men (n=33) included in this 
study was much larger than women (n=14), and there were no individuals with SCI below the 
age of 32 or above age 77. Therefore, any confounding effects of gender or age would have 
been difficult to detect because of the small sample size and unequal number of males and 
females.  Furthermore, it may be that other risk factors may be stronger correlates of aBMD, 
so a relationship between gender and aBMD was not seen. No previous study has examined 
the role of gender and age on average hole size, cortical thickness, buckling ratio, cross-
sectional moment of inertia, and polar moment of inertia in individuals with SCI. However, 
Slade et al [73] and Modlesky et al [72] have examined trabecular bone microarchitecture in 
men and women with SCI at the knee and found similar deteriorations in trabecular bone and 
found fewer trabeculae that are thinner trabeculae and further apart compared to controls. A 
study examining the role of anthropometric and lifestyle factors on trabecular vBMD in able-
bodied men found that age was negatively correlated with cortical and trabecular vBMD 
[140]. Thus, age and gender seem to be important correlates of bone strength variables in 
healthy men and women; whether these factors are important in predicting bone strength in 
individuals with SCI still remains uncertain. Our results must be confirmed with larger and 
more diverse sample populations.  
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 Our results suggest that the initial assessment of the extent of bone loss in individuals 
with SCI should include completeness of injury, duration of injury, bisphosphonate use, and 
fracture history. Gender should also be included in the screening protocol as this risk factor 
was found to be a potential correlate of cross-sectional moment of inertia and polar moment 
of inertia; however further research examining the role of gender and age on other indices of 
bone strength is required as the literature to date is inconclusive and these risk factors are 
strong predictors of fractures in the able-bodied population. Since aBMD is currently the only 
diagnostic tool available for the diagnosis of osteoporosis and fracture risk in the clinical 
setting, duration of injury, completeness of injury, bisphosphonate use, and prior fragility 
fractures should be the primary risk factors examined by clinicians to determine those at high 
risk of fracturing. Future initiatives should also consider the effects of modifiable risk factors 
(alcohol intake [141], physical activity [69], smoking [99], other bone affecting medications, 
such as vitamin D and calcium [142], and BMI [87]) previously found to be correlates of bone 
strength variables in individuals with SCI as our results only account for less than or equal to 
half of the possible outcomes contributing to poor bone strength. The modifiable risk factors 
should be addressed by clinicians during the patient’s initial assessment of bone loss to inform 
the patient of ways to minimize the amount and rate of bone loss. Longitudinal studies are 
needed to have a clearer understanding of the main risk factors associated with bone loss and 
fractures in the SCI population.  
6.3 Indices of Bone Strength Related to Fragility Fractures 
 
 Structure-based measurements may be useful for identifying individuals with SCI at 
high risk of fracture. Our preliminary study found that men and women with chronic SCI and 
fractures had significantly lower bone strength variables than those without fractures. The 
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primary distinctions between the fracture group and non-fracture group was average hole size, 
aBMD in the distal femur, and cross-sectional moment of inertia; individuals with SCI who 
had sustained a fragility fracture have a larger average hole size (intertrabecular spacing) at 
the ultra-distal tibia, and a lower aBMD in the distal femur and cross-sectional moment of 
inertia at the tibia shaft than individuals with no history of fragility fractures. No other 
estimates of tibial bone strength measured by pQCT or DXA discriminated between the 
groups after important clinical correlates were controlled for. It is important to note that 
aBMD at the proximal tibia, trabecular vBMD, and polar moment of inertia were close to 
becoming significant based on the odds ratio and the odds ratio and 95% confidence interval 
suggest they may have become significant with an increase in sample size. Therefore, we 
should not reject the hypothesis that aBMD at the proximal tibia, trabecular vBMD, and polar 
moment of inertia are important correlates of fragility fractures. If we were to conclude these 
non-significant bone variables as having no effect we may be introducing type II error, 
accepting the null hypothesis when the null hypothesis is false. A larger population-based 
study is required to help us identify the true relationship between these indices of bone 
strength and fractures among individuals with SCI. 
Our findings are consistent with the findings of MacIntyre et al [26] who reported that 
postmenopausal women with a history of forearm fractures had significant differences in 
average hole sizes than women with similar aBMD but with no history of fractures. The larger 
average area of the hole size found in individuals with SCI who have fracture may be caused 
by thinning trabeculae and loss of trabecular struts. In nine human cadaver radii, Gordon et al 
[143] demonstrated that changes in trabecular structure are important in determining the 
amount of load that can be withstood prior to fracturing; larger hole sizes in the distal radius 
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are susceptible to collapse under low loading forces. This concept is consistent with previous 
findings that age-related increases in trabecular spacing and thinning of horizontal struts in the 
vertebrae effect the strength of the bone [49,53]. In individuals with SCI, two cross-sectional 
studies reported fewer trabeculae that are thinner and further apart compared to able-bodied 
controls [72,73]. Frost hypothesized that the mineralization and structure of bone is dictated 
by the amount of load imposed on the bone [82,144]. Since some individuals with SCI are 
subjected to no weight bearing, trabecular structure becomes demineralised and deteriorated. 
 aBMD in the distal femur was also found to be a significant correlate of fractures. A 
one SD (1mg/cm
2
) increase in aBMD at the distal femur was associated with a decrease in 
fracture by 1.2%. Areal BMD at the proximal tibia was not a significant factor in 
discriminating individuals with SCI who have fractured to those who have not; however the 
odds did approach significance (p=0.0535) and could possibly become significant with a few 
more concurrent values in both the fracture and non-fracture group. The odds ratio could have 
also been compromised because fewer fragility fractures were seen in the proximal tibia 
(n=11) versus the distal femur (n=14) in our sample population. Furthermore, 20% of the 
fractures occurred in the ankle (n=5) and fibula (n=2); areas where aBMD was not assessed. 
A similar age-adjusted relationship between aBMD and fractures was reported previously in a 
cross-sectional study evaluating BMD and fracture history in individuals with SCI. This study 
reported that for every  10mg/cm
2
 and every unit standard deviation (t-score) decrease in 
aBMD at the femoral neck, the risk of fracturing increased by 2.2 and 2.8 times, respectively 
[14]. The strength of our study is that we adjusted aBMD for completeness of injury and 
bisphosphonate use, correlates found to be associated with aBMD. Our study reported a 
negative relationship between aBMD and the number of fragility fractures sustained. Only 
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one other study assessed this relationship and found a similar  negative relationship [14]. 
Ultimately, these results coincide with previous studies that found aBMD is a correlate of 
fracture risk in individuals with SCI. 
 Cross-sectional moment of inertia may also be an important predictor of fracture risk 
as it was found to be a significant correlate of fractures. De Bruin et al [74] reported that 
individuals with SCI with a fracture had significantly smaller moments of inertia at the 
proximal, distal and middle sections of the tibia compared to able-bodied controls, but there 
was no significant difference between individuals with SCI without fractures. In addition, 
when comparing the bone strength between individuals with SCI who had fractured to those 
who have not, the fractured group had a lower bending stiffness than the non-fractured group, 
suggesting those with fractures are at higher risk of future fractures [74].  Our data is also 
consistent with a prospective study conducted by Sheu et al [80] that found that able-bodied 
men with non-vertebral fractures had lower cross-sectional moment of inertias at the radii 
than those without non-vertebral fractures. Additionally, they found that for every SD 
decrease in cross-sectional moment of inertia, there was approximately 2 fold increase in 
fracture risk [80]. Compared to their results, we found that for every SD decrease in cross-
sectional moment of inertia, the risk of fracturing increased by 90%. The width of bone and 
the thickness of the cortex are key determinants of cross-sectional moment of inertia. Cross-
sectional moment of inertia is best achieved when bone’s cross-sectional area is as far from 
the neutral axis as possible. Individuals with a larger cross-sectional moment of inertia have 
stronger and stiffer bones, while individuals with a smaller cross-sectional moment of inertia 
are weak and usually more prone to bending [145]. During growth, the skeleton responds to 
load by increasing the diameter of long bone via periosteal apposition. However, when there 
83 
 
is an absence or reduction in mechanical loading, the shape and size of bone changes 
[146,147]. In individuals with SCI, the presence of smaller and weaker bones may lead to the 
increased number of fragility fractures. Our study found that a lower cross-sectional moment 
of inertia is associated with fractures, therefore this bone strength variable may have clinical 
relevance as a risk factor in individuals with SCI. Based on the logistic regression analysis 
modeling the relationship between cross-sectional moment of inertia and a fracture, it is 
important to note that the 95% confidence interval was quite wide, therefore we may need to 
perform a similar analysis with a larger sample size to see the true relationship. pQCT is a 
technique that is practical and not costly; therefore, future research should consider examining 
the changes in bone width obtained by pQCT as it may be a strong predictor of fragility 
fractures. 
In our study, cortical thickness was found to be one of the better correlates of fragility 
fractures in individuals with SCI. However, it was no longer statistically significant after 
adjustment for duration of injury. Previous case-control studies have demonstrated similar 
correlations between cortical thickness and fractures. For example, after adjusting for age, 
sex, and weight, Jamal et al [24] reported that a decrease in cortical density, cortical area, and 
cortical thickness were associated with increased odds of fracturing among individuals on 
dialysis. In another study comparing 101 postmenopausal women with and 101 
postmenopausal without prevalent fractures using high resolution pQCT (HR-pQCT) at the 
tibia and wrist, cortical thickness was found to be significantly associated with fragility 
fractures [27]. Our study also found that cortical thickness has an influence on the number of 
fragility fractures, where a thinner cortex leads to more fractures. Individuals with SCI 
experience a decrease in cortical cross-sectional area due to increases in endosteal  and 
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periosteal resorption [19,148]. We need to also consider age-related periosteal apposition 
because periosteal expansion at the tibia may have been reduced following the spinal cord 
injury as these individuals are subjected to little or no weight bearing. When thinned walled 
cylinders are subjected to bending, they tend to fail by buckling; collapsing from the inner 
curvature, rather than cracking from the outer curvature like thick walled cylinders [25]. 
Section modulus characterizes the ability of a thick walled cylinder to resist bending and 
failure. However, section modulus cannot be used to predict failure in thin cortices because it 
would overestimate the amount of load required to cause bone failure [149]. Therefore, the 
thickness of the cortex wall is expressed as buckling ratio. The buckling ratio is bone 
instability depicted by the critical balance between cortical thickness and bone width. Our 
findings suggest that the thinning of cortices plays a key role in the susceptibility to fracture 
by producing an increase in buckling ratio. Although buckling ratio was not a correlate of 
fractures, a relationship was seen between buckling ratio and the number of fragility fractures 
sustained in our cohort. Our data is consistent with a prospective study which reported that 
cortical thickness and area predict incident fractures, whereas buckling ratio does not in men, 
signifying that a narrow bone with a thin cortex can have a low cross-sectional area (CSA) 
and low bending strength, regardless of a normal buckling ratio [145]. In contrary, a previous 
nested case-control study performed in 232 elderly community-dwelling women reported that 
increases in buckling ratio were associated with a higher risk of hip fracture [149]. The 
associations we observed between cortical thickness and fracture may be mediated by 
secondary hyperparathyroidism, a common problem seen in individuals with SCI [150]. 
Hyperparathyroidism occurs as a result of low serum calcium concentrations. Parathyroid 
hormone (PTH) is released in order to stimulate osteoclast resorption to increase levels of 
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calcium in the blood. Studies have found that hyperparathyroidism most likely affects cortical 
bone causing decreases in cortical thickness by endosteal resorption and increases in cortical 
porosity [151,152]. Vitamin D has been identified as being an essential hormone in 
maintaining serum calcium homeostasis and has been shown to have an inverse relationship 
with PTH [152]. In addition, vitamin D has been strongly linked to the maintenance of 
skeletal health in the able-bodied population [153]. Among individuals with SCI, vitamin D 
levels have been reported to be significantly lower than controls [150], and therefore may be a 
contributing factor to decreases in bone health. However, a relationship may exist between 
vitamin D and bone health in the SCI population which may provide therapeutic effects for 
the prevention of fractures in individuals with SCI.  In a randomized control trial, BMD was 
evaluated in individuals in given 4µg/day of vitamin D2 anolog, 800IU/day of vitamin D and 
1.3g/day of calcium (treatment group), and in individuals given a placebo, 800IU/day of 
vitamin D and 1.3g/day of calcium (control group). Leg BMD did not statistically change in 
24 months in the control group; however,  in the treatment group, percent leg BMD increased 
significantly in a subgroup of individuals who had never smoked [142]. The vitamin D 
mediated increase in BMD may be attributable to the prevention of cortical thinning, but there 
are no studies that confirm a clear relationship between cortical thickness or density and 
vitamin D in individuals with SCI. Since cortical thinning has been linked to 
hyperparathyroidism, an exploratory analysis should be conducted to examine the relationship 
between vitamin D or PTH and cortical thickness in the SCI population. If a relationship is 
reported, vitamin D intake would be an important risk factor to include when creating 
guidelines and screening protocols for the prevention and treatment of osteoporosis and 
fracture risk in the SCI population. 
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 The use of pQCT in clinical and epidemiologic research among individuals with SCI 
has been limited. However, there is a growing interest in understanding the changes in bone 
strength after SCI in addition to bone density, as it provides additional information about 
skeletal health. Our data is in line with a number of studies that have demonstrated the utility 
of quantitative computed tomography to detect micro-architectural deterioration in different 
groups with fractures and to detect changes in bone loss over time. Cross-sectional moment of 
inertia, polar moment of inertia, and stress-strain index at the radius have been shown to be 
strong predictors of fracture risk in men with non-vertebral fractures and these pQCT-based 
bone strength variables improved fracture prediction over femoral neck aBMD alone. The 
addition of pQCT-based estimates to aBMD models increased fracture prediction ability by 
approximately 10% [80]. Unfortunately, the addition of pQCT measures of average hole size 
and cross-sectional moment of inertia to models with aBMD at the distal femur in our study 
appeared to decrease fracture correlations. It is likely that our sample size was not large 
enough to answer this question.  Studies have also reported that women with fractures have 
lower trabecular vBMD, cortical thickness, trabecular number and thickness, and higher 
trabecular separation at the radius, and lower cortical thickness, trabecular vBMD, and 
trabecular thickness at the tibia compared with age and aBMD-matched controls without 
fractures [154,155]. Individuals with chronic kidney disease with fractures have significantly 
lower vBMD, cortical thickness and number at the radius and tibia compared with healthy 
matched controls [156,157]. Based on previous studies, it seems that many bone strength 
variables seem to be important determinants of fracture risk in other groups of individuals; 
future research should examine the most useful and appropriate bone strength variables to 
describe fracture risk among individuals with SCI with and without fractures.  
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 The mechanostat theory is a possible explanation for the reduction in bone strength 
experienced in individuals with SCI. This theory suggests that bone strength is adapted by 
strains caused by physiological loads. The largest physiological load exerted on bone is from 
muscle contractions, producing the muscle-bone unit [158,159]. In the able-bodied 
population, many studies have reported strong associations between muscle strength and 
BMC or aBMD [160-163]. There has only been a few studies that have examined the 
relationship between muscle and bone in individuals with SCI. A cross-sectional comparative 
study found a strong linear relationship between BMC and lean tissue mass in the legs among 
individuals with incomplete SCI [88], while a strong relationship between lean tissue and 
BMC in the arms was reported in the monozygotic twin with SCI, regardless of the level or 
completeness of injury [164]. A positive relationship between leg lean tissue and BMC in the 
non-SCI twin was found but there was no relationship found in those with SCI [164]. Since a 
muscle-bone relationship has been reported in individuals with SCI, muscle atrophy is a 
probable explanation for the ensuing decreases in bone strength.  
 Our findings reinforce the importance of bone density obtained by DXA as a clinical 
tool for identifying those who are at high risk of fractures. In addition, we found that 
architectural changes of trabecular and cortical bone obtained by pQCT may refine the ability 
of clinicians to predict fractures. Our results are preliminary; therefore, prospective studies 
need to be performed to confirm the associations we found between indices of bone strength 
and fractures. Furthermore, it is important to determine the most appropriate indices of bone 
strength to identify individuals with SCI at greatest risk for fracturing. Understanding the risk 
factors and changes in bone structure in individuals with SCI will help clinicians pin point 
those individuals who are at greatest risk of fracturing. In turn, clinicians can determine the 
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most appropriate next step to reduce fracture risk whether it is through drug interventions 
such as bisphosphonates [109], vitamin D and calcium [142], or via exercise interventions 
such as functional electrical stimulation (FES) [165].  
6.4 Fracture Threshold and Fracture Breaking Point 
 
 Contrary to our hypothesis, only 7.7% of the sample population had a trabecular 
vBMD fracture threshold of less than or equal to 72mg/cm
3
. In addition, among those who 
had sustained a fragility fracture, only 20% were a risk of fracturing again. Fracture threshold, 
a point at which fractures begin to occur, is being used in the wrong context by Eser et al [30]. 
Since the study conducted by Eser et al [30] has a cross-sectional design, they did not measure 
trabecular vBMD at the time of the fracture; it is incorrect to state that fractures began at a 
trabecular vBMD of 72mg/cm
3 
if the study was not conducted in a prospective manner. 
Therefore, the term ‘fracture breaking point’ would probably be a more appropriate term to 
use in this context. As a result, our data implies that there is a trabecular vBMD fracture 
breaking point at approximately 126mg/cm
3
 in the distal femur, above which no fractures 
have occurred and below which low trauma fractures are common. The present study clearly 
shows that the trabecular vBMD fracture breaking point of the distal tibia previously 
suggested [30] may not accurately predict fracture risk among individuals with chronic SCI. 
Possible reasons for this discrepancy may be the difference in SCI populations studied. The 
study conducted by Eser et al [30], included men with motor complete SCI, whereas the 
present study included men and women with motor complete and incomplete SCI. The 
completeness of injury influences the extent of bone loss that occurs in the lower extremity 
following their injury. Individuals with motor complete injuries experience a greater degree of 
bone loss compared to those with incomplete injuries [2,29,62,87]. This is consistent with our 
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findings in which we found that completeness of injury was related aBMD at the distal femur 
and proximal tibia, trabecular vBMD, cross-sectional moment of inertia, and polar moment of 
inertia. Acknowledging that individuals with complete SCI experience more bone loss than 
individuals with incomplete SCI suggests that perhaps separate fracture breaking points be 
established to distinctly determine fracture risk in both groups. Alterations in muscle mass 
and changes in voluntary muscle contractions exhibited between individuals with complete 
and incomplete SCI may partly elucidate why individual fracture breaking points should be 
created.  Individuals with incomplete SCI experience partial muscle contraction thus exerting 
forces indirectly on bone, while individuals with complete SCI experience complete 
inactivation of muscle fibres, exerting no forces on bone; as a result, there is greater muscle 
atrophy in the lower extremity among those with complete SCI than incomplete SCI. The 
muscle-bone relationship [160] directly explains why individuals with incomplete SCI may 
have a higher fracture breaking point than individuals with complete SCI; a higher force is 
required to cause a fracture among individuals with complete SCI. Our fracture breaking point 
is approximately 75% higher than the recommended 72mg/cm
3
 threshold. However, if 
individuals with motor incomplete SCI were removed from the analyses, the fracture breaking 




 higher than the previously recommended trabecular 
vBMD fracture breaking point. According to our findings, individuals with SCI seem to be 
fracturing despite having higher BMD. Many of our subjects were on interventions such as 
bisphophonates, calcium, vitamin D supplements, and multivitamins which may account for 
the higher BMD. Strong inhibitors of bone resorption, such as bisphosphonates can reduce the 
activation frequency and mineralizing surface by 87% and 92%, respectively causing 
increases in bone mineral density [166]. In our study, we were able to demonstrate that 
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bisphosphonate use is related to bone density at the knee. Therefore, the true fracture breaking 
point may be masked due to the high proportion of individuals on treatments to improve bone 
health. Another possible reason for the discrepancy may be because our sample population 
had greater skeletal heterogeneity, producing more differences in bone structure deterioration 
from one individual to another. Finally,  values of trabecular vBMD may be different because 
Eser et al [30] used the XCT 3000 pQCT while we used the XCT 2000 pQCT. The XCT 3000 
provides a larger gantry than the XCT 2000 in order to better accommodate larger limbs such 
as the lower leg. A study comparing measurements in the distal radius obtained by XCT 3000 
and XCT 2000 found a strong correlation (r=0.99) between the two devices when measuring 
trabecular vBMD and a mean difference  (XCT 3000-XCT 2000) expressed as a percent of 
the measurement’s mean of only 1.9% [167]. Therefore, the difference in devices used should 
only account for a small difference and not the large difference we observed in trabecular 
vBMD fracture breaking point. Eser et al [30] also reported using a higher contour threshold 
of 180mg/cm
3
 compared to our 130mg/cm
3
. The contour mode detects the outer bone edge 
(periosteal boundary) and provides information on total bone parameters, while the addition 
of a threshold provides a boundary line which informs the software of a starting position in 
which to begin analysis. When a higher threshold is used, the software will cut away some of 
the bone, causing the segmented bone structure to become small. We decided to use a lower 
threshold in order to include areas of lower trabecular density in addition to the denser 
trabecular area. Although, in a validation study previously conducted, we have found that 




 does not dramatically change 
trabecular vBMD (unpublished data, Appendix B). 
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 Of 47 subjects, approximately 30% had sustained at least one fracture in the lower 
extremity. Our results are in between previous reports which found 25% [30] and 34% [14] of 
their study sample had experienced at least one fracture. We found that fractures generally 
occurred more frequently in the femur than in the tibia, which is in agreement with previous 
studies [7,8,11,13]. In addition, our study confirms the notion that fractures of the lower 
extremities are more common in subjects with paraplegia than tetraplegia [8], probably due to 
their higher activity levels and mobility. We found only 11 fractures occurred in participants 
with tetraplegia and 23 fractures occurred in participants with paraplegia.  
 The indices of bone strength were significantly lower in those individuals with a 
fragility fracture compared to those without. Therefore, it is important that clinicians obtain 
fracture history following a SCI in order to determine the prevalence of fractures in those 
individuals with trabecular vBMD below the fracture threshold. Due to the discrepancy seen 
in trabecular vBMD fracture threshold of the tibia, further investigations and evaluations are 
required with a larger and more diverse sample population. Ultimately, the fracture threshold 
concept could be used as a diagnostic technique for fracture risk assessment in individuals 
with SCI. 
6.5 Limitations  
 
Although this study provides important information in our understanding of 
subsequent fragility fractures among individuals with chronic SCI, there are several 
limitations. First, we did not match cases (fragility fractures) and control (no fragility 
fractures). Our sample included many more controls than cases for the logistic regression. The 
number of individuals with fragility fractures was 14, which represents only 29% of the 
sample size, while then number of individuals with no history of fractures was 33, 
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representing 71% of the sample size. The sample size among individuals with fractures 
further decreased due to missing bone strength variables, reducing the sample size to ten for 
the following indices of bone strength: aBMD of the distal femur, vBMD, average hole size, 
cortical thickness, and buckling ratio. The sample size seemed to be small when performing 
odds ratio and 95% confidence interval obtained by multivariable logistic regression models 
to identify indices of bone strength associated with having at least one fracture. If we were to 
redesign this study, creating a priori matching criteria would help us eliminate other 
confounding variables. Based on the sociodemographic and impairment characteristic chart 
(Table 6), adjusting for injury characteristic (p=0.033), AIS (p=0.018), and LEMS (p=0.008) 
would help eliminate the matching limitation. In addition, BMI should also be considered as a 
risk factor since it has been found to be a correlate of bone density. We chose to not include 
BMI as a confounding variable because it fails to identify persons with SCI who are truly 
obese [91]. Finally, the sample population with fractures needs to be larger in order to 
improve the effect size and increase the statistical power of the results. 
Another weakness in the present study is that bone status was not measured at the time 
of the fragility fracture. In several cases, the fractures occurred years (approximately 6 years) 
before the bone measurements were made in the study, thus, a causal relationship between 
fractures and indices of bone strength could not be established. A prospective study needs to 
be performed to identify an actual causal relationship. Furthermore, a large number of our 
sample population was recruited by physician referral from the bone clinic at the Lyndhurst 
Centre. As a result, many of participants for this study were on interventions to improve bone 
health such as calcium (n=40), vitamin D (n=42), bisphosphonates (n=26), and exercise. 
Therefore, the results of this study may not be generalizable to all individuals with chronic 
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SCI, as bone health may have improved since the occurrence of the fractures, resulting in 
higher bone quality measurements.  
We did not consider the role of bisphosphonates as an effect modifier. The term ‘effect 
modification’ is applied to indicate that the effect of a particular variable (aBMD) on another 
(fractures) varies according to a third factor (bisphosphonates). There has been considerable 
concern that long-term bisphosphonate use might be adversely affecting bone quality in 
postmenopausal women. There have been reports of an unusual (atypical) type of bone 
fracture that are low energy femur fractures, typically transverse or slightly oblique at the 
diaphysis or subtrochanteric.  Furthermore, these individuals with atypical fractures have a 
higher ratio of cortical thickness to femoral diameter than individuals with normal fracture 
patterns [112]. A recent population-based nested case control study found that women taking 
bisphosphonates for five or more years were at increased risk of subtrochanteric or femoral 
shaft fractures (OR=2.74 95%CI=1.25-6.02) compared with transient bisphosphonate users. 
The study found that 71 (0.13%) and 117 (0.22%) out of 52 595 women with at least five 
years of bisphosphonate therapy sustained a femoral fracture within the subsequent year and 
within two years, respectively [168]. Based on our data collection assessment forms, we were 
unable to determine whether fractures were due to bisphosphonates. We know the number of 
individuals who were currently on bisphosphonates at the time of the assessment, but we do 
not know whether they were taking the drugs when they sustained their fragility fracture. 
Before the larger prospective study, Bone Quality in Individuals with SCI moves forward, it is 
critically important to fix the fracture ascertainment form (Appendix A). Table 16 outlines 
possible questions that should be considered to help us determine if their fragility fractures 
were caused by bisphosphonates. 
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Table 16: Possible Questions to be Included in the Fracture Ascertainment Form 
Questions 
1. Were you on bisphosphonates when you fractured?  
2. How long were you on bisphosphonates? (Provide approximate dates) 
3. Which bisphosphonates were you on? What was the dose? 






Fourthly, four pQCT scans at the ultra-distal tibia (4% site) and two pQCT scans at the 
proximal one-third of the tibia (66% site) had very minor movement artefacts and were not 
removed from the analysis. However, the scans were still of good quality and did not affect 
the integrity of cortical circumference. There were also three pQCT scans at the proximal one-
third of the tibia (66% site) that had clearly visible movement artefacts with disruption in 
cortical edge causing them to be of insufficient quality, but were also kept in the analysis. 
Partial volume effect (PVE) could also cause inaccurate estimates of bone strength variables 
obtained by pQCT. PVE occurs when a single voxel contains tissues of different densities, 
such as the boundary between bone tissue and soft tissue, and therefore the attenuation 
coefficient assigned is some middle ground between the two. Movement artefacts and PVE 
could have caused overestimations or underestimations in bone strength variables, decreasing 
the accuracy of pQCT-based measurements. However, we found that removing the scans with 
movement artefacts only resulted in very small changes in the associations between fractures 
and bone strength variables. 
Finally, there are some potential measurement biases that must also be considered 
when making conclusions about this study. Using recall to ascertain an outcome has its 
problems. Fractures may be underreported due to lack of saliency of the exposure and 
subsequent poor recollection of fractures that occurred in the past, leading to reporting bias. 
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Reporting bias would predominately affect the observed association by underestimating 
overall events, making the association between fragility fractures and indices of bone strength 
appear weaker than it may be. The current work confirms that fragility fractures are common 
among individuals with chronic SCI; however the number of individuals with fragility 
fractures may be higher than estimated. 
6.6 Conclusion 
 
In summary, we found that gender, completeness of injury, duration of injury, 
fractures, bisphosphonate use were associated with indices of bone strength in individuals 
with SCI. Our findings also suggest that, in individuals with SCI, aBMD at the distal femur, 
average hole size at the ultra-distal tibia, and cross-sectional moment of inertia were the best 
correlates of fragility fractures. However, we found that each of the indices of bone strength 
were able to model the number of fragility fractures sustained. Our data supports a trabecular 





 for individuals with complete SCI and those with incomplete SCI, respectively. 
The findings presented in this study provide the framework for future enquiry of the 
relationship between indices of bones strength assessed non-invasively by pQCT and fragility 
fractures and the risk factors associated with lower extremity osteoporosis. Further studies are 
needed to determine the most appropriate risk factors that contribute to bone loss and 
understand the role and importance of these and other indices of bone strength on skeletal 
fragility in individuals with SCI. Prospective studies should also be undertaken to determine 
whether indices of bone strength by pQCT can predict the risk of multiple frailty fractures. In 
due course, a fracture prediction model integrating various risk factors and indices of bone 
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strength can be developed to evaluate fracture risk of individuals with SCI, which in turn can 
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Dear  <Name>: 
 
 
You are being asked to take part in a research study called “Bone quality in 
individuals with chronic SCI”. Myself and other researchers at McMaster University, the 
University of Waterloo, University of Toronto and the Toronto Rehabilitation Institute are 
conducting the study.  The Canadian Institutes of Health Research are funding this study 
(www.cihr-irsc.gc.ca). The purpose of the study is to examine the bone health of men and 
women with chronic spinal cord injury.  
If you agree to take part in the study, you will be asked to have your bone density 
measured once a year for 2 years.  You will also be asked to report your past and current 
medical history and medications, followed by a brief examination of your sensation and 
muscle activity. You will participate in two types of bone density scans in the study; one at 
Lyndhurst and one at McMaster University. Transportation to McMaster University will be 
provided.  The overall time commitment for the study is 10-15 hours over the 2 year period.  
This includes three visits to Lyndhurst (2-3 hours each) as well as three visits to McMaster 
(30 minutes each) and five telephone follow-up calls (30 minutes each).  All participants will 
receive a $40 honorarium at the 0 (start), 1 year and 2 year time points. 
At some point in the next two weeks you will receive a telephone call from a research 
assistant. The assistant will ask you if you are interested in participating in this study. If you 
are not interested, you can tell the assistant at this time. If you would prefer not to have the 
assistant call you at all, please call (416) 597-3422, extension 6301. Leave a message with 
our research coordinator, Lindsie Robertson, saying that you would prefer not to be 
contacted.   Alternatively, you can also e-mail robertson.lindsie@torontorehab.on.ca.  
It is important for us to know if people who participate in the study are very different 
from people who choose not to participate. If you choose not to participate, the research 
assistant will ask you if you mind answering a few brief questions, such as your age or 
Primary Investigators: 
Dr. Lora Giangregorio
Dr. Catharine B. Craven 
 
Co-investigators: 
Dr. A. Papaioannou 
Dr. M. Popovic 
Dr. L. Thabane 
Dr. N. McCartney 
Dr. J.D. Adachi 
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whether you have ever broken a bone before. Your name will not be stored with this 
information. You can choose not to answer these questions if you wish. 
If you decide to participate in the study, all information you provide will be 
confidential. Your name will not appear on any forms. You can stop participating at any time 
without having to give a reason.  A decision not to volunteer or to withdraw from the study 
after you have enrolled will not have any impact on the care you receive at Lyndhurst. If you 
have any questions about the study you can contact Lindsie Robertson at the number listed 
above or Dr. Cathy Craven at (416) 597-3422 extension 6122.  
Your contribution to this research will help us better understand who is at risk for 
bone loss and broken bones. We eventually want to understand better ways to diagnose and 







insert physician name here 
 
This study has been reviewed and received ethics clearance through the Office of Research 
Ethics at the University of Waterloo, the Research Ethics Board at the Toronto Rehabilitation 
Institute and the Research Ethics Board of Hamilton Health Sciences/McMaster University 
Faculty of Health Sciences.. If you have any questions regarding your rights as a research 
participant, you may contact: Dr. Gaetan Tardif, Research Ethics Board at (416) 597-3422 x 
3730 or Dr. Susan Sykes University of Waterloo Research Ethics Board at 519-888-4567, x 
36005, ssykes@uwaterloo.ca or Office of the Chair of Hamilton Health Sciences/Faculty of 

























RESEARCH:  Bone Quality in Individuals with Chronic Spinal Cord 
Injury 
 
Background: A cohort of 80 adult men and women, with traumatic SCI, two years 
post-injury, will be established. Data collected will include: medical history; bone 
density (BMD) and body composition; tibia volumetric BMD, bone geometry, muscle 
area and trabecular structure; and x-ray reports to verify fractures (if any). Data will 
be collected at 6 month intervals over a 24 month period.  This research will form the 





Patient has verbally consented to the above personal health 
information being forwarded to a research team member and being 









Please forward to Lindsie Blencowe (x6301, room 206-D)  
 
 





     ______________________________________________ 




Assessors Initials:  
 




Gender:  M   F    
 
If potential participant is eligible for the study, arrange for a visit to Lyndhurst to 
complete information and consent form and first testing visit (if consent is provided). 
 
Inclusion Criteria Yes No Comments 
1. Participant is ≥18 years of age     
2.  
Participant is able to understand instructions in 
English. 
   
3. 
“What is the level of your spinal cord injury?” 
Potential participant has a level of injury at or 
between C2 and T12 
  




“What was the cause of your spinal cord 
injury?” 
Potential participant has a neurological 
impairment secondary to a spinal cord injury of 
sudden onset (<24 hours onset).  
  




5.   
“When did you have your spinal cord injury?” 
Potential participant’s spinal cord injury 
occurred at least 24 months prior to screening. 
  
Date of Injury:  
/ /  
 Y  Y  Y  Y   M  M D  D 
6.   
“Do you know if you have or have had any 
conditions that might affect your bones, such 
as cancer or liver disease?” Potential 
participant has no secondary causes of 
osteoporosis. 
   
7.
0 
“Are you willing to attend three visits to 
Lyndhurst and three visits to McMaster 
University over the course of two years?” 
Potential participant is willing to attend 3 visits 
to Lyndhurst & McMaster. 
   
Telephone Screening Form 
Y Y Y Y M M D D 
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Title of Study: Bone Quality in Individuals with Chronic Spinal Cord Injury 
Primary Investigators:  Dr. Lora Giangregorio and Dr. Catharine B. Craven 
Co-investigators: Dr. Papaioannou, Dr. Popovic, Dr. Thabane, Dr. McCartney, 
and Dr. Adachi 
Student Investigators: Kayla Hummel, Deena Lala, and Julia Totosy de 
Zepetnek, Dept. of Kinesiology, University of Waterloo 
Sponsor: Canadian Institutes of Health Research, Ontario Neurotrauma 
Foundation, and SCI Solutions Network 
 
 
You are being invited to participate in a research study. To decide whether or 
not you want to be a part of this research study, you should understand what is 
involved and the potential risks and benefits. This form gives detailed 
information about the research study, which will be discussed with you. Once 
you understand the study, you will be asked to sign the form at the end of this 
information letter if you wish to participate. If you are not able to sign the form 
but are able to provide verbal consent, it will be documented by the person 
obtaining consent. Please take your time to make your decision. Feel free to 
discuss it with your friends and family, or your family physician. 
 
WHY IS THIS RESEARCH BEING DONE? 
 
Individuals with spinal cord injury (SCI) often experience bone loss. Bone loss 
can cause a person to be more likely to break a bone in the future. We are 





Dr. Catharine B. Craven 
 
Co-investigators: 
Dr. A. Papaioannou 
Dr. M. Popovic 
Dr. L. Thabane 
Dr. N. McCartney 
Dr. J.D. Adachi 
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WHAT WILL I BE ASKED TO DO IF I DECIDE TO TAKE PART IN THE 
STUDY? 
 
This study will require 10-15 hours of your time over a 2 year period.  
This study is being conducted at multiple sites. You may participate at 
Lyndhurst Hosptial (Toronto) OR Chedoke Hospital (Hamilton) – whichever is 
most convenient for you. 
 
If you decide to participate in the study, we will ask you to do the following 
things: 
Visit to Lyndhurst or Chedoke 
 Complete a medical history that asks questions about your injury 
characteristics as well as your past and current medical health, medications 
and lifestyle. You may be asked to have an ASIA exam, which tests your 
sense of touch and your sense of movement, if we do not have record of an 
exam for you. This will take approximately 45 minutes. 
 On your first visit to Lyndhurst, you will be asked to provide a blood sample. 
Fasting conditions will be required.  Participants will be asked to fast for at 
least 12 hours.  For those participants unable to fast, a breakfast of toast and 
apple juice or orange juice will be allowed and blood will be drawn 4 hours 
after.  The blood sample will be used to measure protein markers of bone 
metabolism, vitamin D, parathyroid hormone (PTH), and ionized calcium 
levels in your blood. The blood sample will be draw by a trained 
phlebotomist.  We will take about two tablespoons of blood by inserting a 
needle in a vein in your arm.  
 Participate in 1 set of 6 bone density scans. Bone density scans are x-rays 
that measure how much bone mineral you have in certain bones. Individuals 
with low amounts of bone mineral may be at increased risk of fracture. The 
scans will be taken of your hips, above and below your knee, your spine and 
your whole body. During the scans you will be transferred to a scanning 
table. If you are not able to transfer yourself, we will use a special lift device. 
You will not feel anything when the scanner is on. The scanning will take 
approximately 60 minutes. 
 Complete some questionnaires by phone three days after your visit.  The 
questionnaires will gather information regarding your activity and diet.  This 
telephone call will last approximately 30 minutes. 
 
Visit to McMaster  
 Participate in a second visit at McMaster University Medical Centre for a 
second type of bone density scan.  The scanner is called a peripheral 
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quantitative computed tomography scanner and also uses x-rays to measure 
bone density.  During this visit, you will be asked to participate in 1 set of 3 
scans that measure the shape and structure of your bones. A researcher will 
take 3 scans, one at your ankle, the second at mid-calf and the third at the 
widest cross-section of your calf. During the scans the limb being measured 
will be placed in a positioning device.  Please refer to the pictures we have 
provided. We will conduct the scans while you are seated in a chair or 
wheelchair. You will not feel anything when the scanner is on. This visit will 
take 45 minutes.  
 
Yearly Follow-up for 2 years 
 You will be asked to return annually for the next two years to repeat the 
medical history, bone density scans, and scans at McMaster. You will be 
called at 6 and 18 months during the two year study to monitor any changes 
in your health, medication and record if you have had any fractures.  You 
will also be asked to report any broken bones to the study coordinator over 
the two-year period when they occur.   These phone calls will take 
approximately 30 minutes or less. 
 
If you have severe spasticity: During the scans at McMaster, it may be difficult 
for the technologist to position you if you have lower body muscle spasms. Only 
if you have severe lower body muscle spasms, you will be asked to take a 
small dose of Lorazepam (otherwise known as Ativan, dose is 0.5-1.0 mg below 
the tongue) to prevent spasms while the scan is taking place. If you do not have 
severe spasticity, you will not need to take Lorazepam. Lorazepam is a short 
acting muscle relaxant that reduces muscle spasms.  Many people with SCI have 
taken Lorazepam early after their injury to help with sleeping while in hospital. 
Adverse reactions to Lorazepam, when they occur, are usually observed at the 
beginning of the dose and generally decrease in severity or disappear after 2-3 
hours.  If you become very drowsy with Lorazepam, you may not remember 
having the pQCT scan. If needed, the Lorazepam will be prescribed for you by 
Dr. Craven on the day of your scan. These precautions are taken mainly to 
reduce the chance of injury in the event that a spasm occurs when your leg is 
placed in the scanning device. You do not have to agree to take Lorazepam if 
you do not wish to do so. However, we may decide not to try to scan you if the 
spasticity limits our ability to position you safely. If you have metal implants in 
both lower legs, have broken your shinbones in the past, or have severe leg 
spasms and are allergic to Lorazepam, you will not be able to participate in the 
study. Also, women who may be pregnant or who plan on becoming pregnant 
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cannot participate.  If you are a woman, a urine pregnancy test may be 
performed to ensure that it is safe for you to participate. 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? 
 
The risks to participants are small. Bone Density scans involve exposure to 
small amounts of radiation. The level of exposure associated with the scans 
proposed in this study is ~30 Sv, which is less than doses received during a 
computed tomography (CT) scan of the chest (30-60Sv) or annually from 
background radiation (2500 Sv). The radiation dose is roughly equal to the 
dose of radiation received over 3 days by every Canadian from natural sources 
of radiation in the environment.  Repeated exposure to radiation has a 
cumulative risk over time but the radiation risk from participating in this study 
considered minimal.  
 
If you are asked to take Lorazepam to reduce your leg spasms during scans in 
Hamilton, there is a risk of side effects.  Amongst a study of 3500 people, the 
most common side effects were sedation (15.9%), dizziness (6.9%), weakness 
(4.2%) and unsteadiness walking (3.4%). Less frequent side effects include 
disorientation, depression, nausea, change in appetite, headache and agitation.  
Most side effects, if they occur, occur with the first dose of the drug.  
Lorazepam will only be given to you if necessary.  If you need Lorazepam, it 
will provided to you at no cost.  After taking Lorazepam, the study staff will 
monitor you for an hour or so, to make sure you have not had any side effects.  
A physician will be available for supervision. You should not drive or perform 
other tasks that require alertness immediately after taking Lorazepam. Also, you 
cannot take Lorazepam if you are currently taking the fungal medications 
ketoconazole (Nizoral or Xolegel) or itraconazole (Sporanox).   
 
Women who may be pregnant or who plan on becoming pregnant cannot 
participate in the study as there are risks to exposing a fetus or unborn baby to 
ionizing radiation. 
 
Fasting blood draws can also have side effects and discomforts.  Fasting may 
cause hunger, headache, dizziness and/or weakness.  As a result of the blood 
draw, there is a possibility that you may experience pain, bruising, bleeding or 
infection at the site of the needle puncture. Blood draws may also temporarily 
cause headache, nausea and lightheadedness. 
 




80 individuals with SCI will be recruited to participate.  
 
WHAT ARE THE POSSIBLE BENEFITS OF THE STUDY FOR ME 
AND/OR SOCIETY? 
 
We cannot promise any personal benefits to you from your participation in the 
study. If you are interested in learning what your bone density is, we can send 
your bone density scan results to your physician. The study will help us 
understand bone loss in individuals with SCI, and determine risk factors related 
to bone loss in SCI. 
 
CONFIDENTIALITY AND SECURITY OF DATA 
 
Your data will not be shared with anyone except with your consent or as 
required by law. All personal information will be removed from the data and 
will be replaced with a number. A list linking the number with your name will 
be kept in a secure place, separate from your file. The data will be securely 
stored in a locked office. For the purposes of ensuring the proper monitoring of 
the research study, it is possible that a member of the Office of Research Ethics 
at the University of Waterloo, Hamilton Health Sciences Research Ethics Board 
or Toronto Rehab Research Ethics Board may consult your research data and 
medical records. However, no records that identify you by name or initials will 
be allowed to leave the hospital. By signing this consent form, you authorize 
such access. If the results of the study are published, your name will not be used 
and no information that discloses your identity will be released or published 
without your specific consent to the disclosure. However, it is important to note 
that a copy of your signed consent form and the data that follows may be 
included in your health record.  The data will be retained indefinitely. 
 
CAN PARTICIPATION IN THE STUDY END EARLY? 
 
If you volunteer to be in this study, you may withdraw at any time and this will 
in no way affect the quality of care you receive at this institution. You have the 
option of removing your data from the study. You may also refuse to answer any 
questions you don’t want to answer and still remain in the study. The 
investigator may withdraw you from this research if circumstances arise which 
make it unsafe for you to continue participating and it is in your best interest to 
withdraw.  You will also be informed in a timely manner of any new 
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information that arises during the course of the study that may influence your 
decision to participate.  
 
WILL I BE PAID TO PARTICIPATE IN THIS STUDY? 
 
You will receive a $40 honorarium to participate in the study. We will provide 
transportation for the study visits and you are welcome to have someone 
accompany you on the trip. For those wishing to use their own transportation for 
travel, we will reimburse the costs of parking and mileage ($0.50 per kilometer) 
associated with participating in the study. 
 
WILL THERE BE ANY COSTS? 
 
Your participation in this research project will not involve any additional costs 
to you or your health care insurer. 
 
WHAT HAPPENS IF I HAVE A RESEARCH-RELATED INJURY? 
 
If you are injured as a direct result of taking part in this study, all necessary 
medical treatment will be made available to you at no cost. Financial 
compensation for such things as lost wages, disability or discomfort due to this 
type of injury is not routinely available. However, if you sign this consent form 
it does not mean that you waive any legal rights you may have under the law, 
nor does it mean that you are releasing the investigator(s), institution(s) and/or 
sponsor(s) from their legal and professional responsibilities. 
 
IF I HAVE ANY QUESTIONS OR PROBLEMS, WHOM CAN I CALL? 
 
If you have any questions about the research now or later, if you wish to 
withdraw from the study at any time or if you think you have a research-related 
injury, please contact the research coordinator for the study, Lindsie Robertson 
at (416) 597-3422 x6301, pager (416) 644-6936 or one of the study investigators 
below: 
Dr. Craven (416)597-3422 x6122  
Dr. Lora Giangregorio (519) 888-4567 x36357 
Kayla Hummel via e-mail, khummel@uwaterloo.ca  
 
This study has been reviewed and received ethics clearance through the Office 
of Research Ethics (ORE) at the University of Waterloo, the Research Ethics 
Board at the Toronto Rehabilitation Institute and the Research Ethics Board of 
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Hamilton Health Sciences/McMaster University Faculty of Health Sciences.  If 
you have any questions regarding your rights as a research participant, you may 
contact any/all of the offices listed below: 
 
Office of Research Ethics (ORE) at the University of Waterloo (519) 888-4567 
x6005  
 
Dr. Gaetan Tardif - Chair, Toronto Rehab Research Ethics Board (416) 597-
3422 x 3730 
 
Office of the Chair of Hamilton Health Sciences/Faculty of Health Sciences 
Research Ethics Board (905) 521- 2100 x42013 
IF I DO NOT WANT TO TAKE PART IN THE STUDY 
 
It is important for you to know that you can choose not to participate in the 
study. Your doctor can do tests to look at your bone density even if you do not 
participate in this study.  Choosing not to participate will in no way affect the 
regular therapy or health care that you receive.  
 
If do not want to participate, it is important for us to know if there are significant 
differences between people who choose to participate in our study and people 
who don’t. We ask if you would mind answering 7 brief questions that will be 
used to determine if the group of people who did not participate are different 
than those who did. You can also choose not to answer these questions, it is 
entirely your decision.  If you do not want the be in the study but might want to 
answer the questions, we will review them with you and let you decide. Neither 





SIGNATURE OF PARTICICIPANT/LEGALLY-AUTHORIZED 
REPRESENTATIVE 
 
I have read the preceding information thoroughly. I have had the opportunity to 
ask questions, and all of my questions have been answered to my satisfaction. I 
agree to participate in this study. I understand that I will receive a signed copy of 
this form.  
 
______________________________________ 
Name of Participant  
 
______________________________________  ______________ 
Signature of Participant      Date 
 
If verbal consent is obtained in lieu of a signature, the person obtaining consent 
will initial here: ______________________ 
 
 
Consent form administered and explained in person by: 
 
I confirm that I have explained the nature and purpose of the study to the 
participant name above.  I have answered all questions.  I believe the participant 




Name and title 
 
______________________________________  ______________ 
Signature        Date 
 
SIGNATURE OF PRINCIPAL INVESTIGATOR: 
 
I have delegated the informed consent discussion to      
 
 
______________________________________  _______________ 
Signature of Principal Investigator    Date  
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Access to Medical Charts 
 
 
Title of Study: Bone Quality in Individuals with Chronic Spinal Cord Injury 
Primary Investigators:  Dr. Lora Giangregorio and Dr. Catharine B. Craven 
Co-investigators: Dr. Papaioannou, Dr. Popovic, Dr. Thabane, Dr. McCartney 
and Dr. Adachi 
Student Investigators: Kayla Hummel, Deena Lala, and Julia Totosy de 
Zepetnek, Dept. of Kinesiology, University of Waterloo 
Sponsor: Canadian Institutes of Health Research, Ontario Neurotrauma 
Foundation, and SCI Solutions Network 
 
We would like to access your medical chart to verify your medical history. We 
would like to confirm your ASIA classification to see if it has changed, check 
your surgical and medical history and see any bone density scans you have had. 
By signing below, you are giving your consent to allow the coordinator of the 
study and lead investigators to look at your chart. You have the right to choose 
not to have anyone look at your chart if that is your wish.  The information 
collected from your chart will be used for research purposes only. 
 
Consent to give access to chart at Toronto Rehab: 
 
 
________________________    ______________________    ____________ 





















Assessors Initials:  
 






     Gender:               Male               
Female 
Date of Birth: / /  
                                      Y       Y      Y      Y       M      M        D       
D 
Date of injury/onset:  
 
           / /  
                 Y       Y       Y      Y       M      M        D       D  
Time Post Injury:   years 
 Level of Injury  (e.g. T12, C06):   
          N/A 
Cause of injury : 
___________________________ 






ASIA Total Motor Score:  
 
ASIA LEMS:  
 




Past Medical History 
Visit 01 
Y Y Y Y M M D D 




Assessors Initials:  
 






Past Medical History 
Visit 01 
Y Y Y Y M M D D 




Assessors Initials:  
 





Past Medical History 
Visit 01 
Y Y Y Y M M D D 




 Assessors Initials:  
 





   
    HAVE YOU EVER BROKEN A BONE BEFORE?   YES  NO 
 
IF YES, PLEASE COMPLETE THE FOLLOWING FOR EACH FRACTURE EVENT: 
 
 
1. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI 
                     Y       Y       Y      Y       M      M        D       D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:             
  
 




2. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI 
                     Y       Y       Y      Y       M      M        D       D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:             
            




Past Medical History 
Visit 01 
Y Y Y Y M M D D 






Assessors Initials:  
 




   
3. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI 
                     Y       Y       Y      Y       M      M        D       D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:             
  
 




4. BONE FRACTURED:         
 
WHEN IT OCCURRED: / /      BEFORE SCI   AFTER SCI 
                     Y       Y       Y      Y       M      M        D       D 
 
HOW DID FRACTURE OCCUR?: 
 TORSION  LOW VELOCITY FALL   ROM 
HYPERFLEXION TRANSFER  OTHER specify:     
 
 
FRACTURE VERIFIED BY MEDICAL RECORDS:   YES   NO    
 
NOTES:             
            
   
 
 
Additional sheets as needed 
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 




Assessors Initials:  
 






HAVE YOU TAKEN CALCIUM OR VITAMIN D SUPPLEMENTS IN THE PAST? 
 
 
Calcium Supplement    Yes          No          Unknown   If Yes, Mg per day: 
      
 
Type of Calcium Supplement :    Calcium Carbonate     Calcium Citrate  
Unknown        
 
               Other (Specify): ________________  




Vitamin D     Yes            No           Unknown 
 
If Yes, (iu) per day:   Duration (months):  
 
 
Multivitamin     Yes            No           Unknown 
 
Duration (months):  
 
  
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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HAVE YOU EVER BEEN PRESCRIBED A BISPHOSPHONATE?      
 
Didrocal (Etidronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Fosamax (Alendronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Actonel (Risedronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Aredia (Zolendronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Bonefos/Clasteon/Ostac 
(Clodronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Skelid (Tiludronate) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   




  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   




  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   





Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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PAST MEDICATION ADVERSELY AFFECTING BONE DENSITY 
 
HAVE YOU EVER BEEN PRESCRIBED ANY OF THE FOLLOWING?  
 
Prednisone 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Tegretol or Dilantin 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Thyroid Medication 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Coumadin (Warfarin) 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 




  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   





  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
 
 
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Testosterone tablets or gel 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Miacalcin 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Other: (Specify):  
 
_______________ 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Other: (Specify):  
 
_______________ 
  Yes       No 
 
  Unknown 
If Yes,  # months :  
Adherence : 
 0%-25%    26%-50%   
 51%-75%  76%-100% 
Past Medical History 
Visit 01 
Y Y Y Y M M D D 




-Assessors Initials:  
 




 X-RAY - Post SCI of the hip or knee region: 
  
Date:        / /  Anatomic Location :     
                         Y       Y       Y      Y       M      M        D       D 
      
      
 
If yes, Complete description of fracture location and type in the table below:  






























































Answer only if x-ray was done of the hip/ knee region:  
Subluxation:                                         
Dislocation:                 
Avascular Necrosis:                      
Heterotopic 
Ossification:                     
Prior Surgery:                 
 
Comments:           
            
     
Past Medical History 
Visit 01 
Y Y Y Y M M D D 
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  Dates of Use 









Oral   
IV   
IM   
SC   
Rectal   




QD   
BID 
TID 
QID   
HS 
PRN   
Other:  
 
Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
 
Stop Date : 
/ /  












Oral   
IV   
IM   
SC   
Rectal   




QD   
BID 
TID 
QID   
HS 
PRN   
Other:  
 
Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
 
Stop Date : 
/ /  












Oral   
IV   
IM   
SC   
Rectal   
Topical   
Other:  
Frequency 
QD   
BID 
TID 
QID   
HS 




Start Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
 
Stop Date : 
/ /  









Y Y Y Y M M D D 




Assessors Initials:  
 




HEIGHT:  .  cm          
 
 Not Available 
WEIGHT:  .  kg         
 
 Not Available 
WAIST CIRCUMFERENCE:  .  cm         Not Available                                          




ARE YOU PRE-MENOPAUSAL, PERI-MENOPAUSAL OR POST-MENOPAUSAL? 
If they are unsure, skip to next question.  
 PRE  PERI   POST 
 
If they are pre- or peri-menopausal, or unsure ask: HOW LONG AGO WAS YOUR LAST 
PERIOD?  (do not count periods that occurred while taking hormones) 
 
 LESS THAN ONE YEAR  1-3 YRS  
 3-10 YRS  MORE THAN 10 YEARS 
 
If they are post-menopausal, ask: WAS YOUR LAST PERIOD GREATER THAN 10 
YEARS AGO? 
 NO  YES 
 
If NO, ask: WAS YOUR LAST PERIOD LESS THAN 5 YEARS AGO? 
 NO  YES 
 
HAVE YOU EVER HAD A HYSTERECTOMY OR HAD BOTH YOUR OVARIES 
REMOVED OR RADIATED?   






Y Y Y Y M M D D 
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DO YOU CURRENTLY SMOKE?   YES     NO #/DAY      
 
HAVE YOU EVER BEEN A SMOKER?   YES   NO   
      
IF YES TO ABOVE, PLEASE WRITE DOWN WHEN THEY STARTED AND STOPPED SMOKING (YEAR). 
ALSO PLEASE INDICATE HOW MANY CIGARETTES PER DAY, ON AVERAGE. IF AMOUNT SMOKED 
VARIED OVER TIME, PLEASE DESCRIBE. 
 
START   STOP   #/DAY  
            Y Y  Y Y              Y  Y  Y  Y   
 
 
DO YOU CURRENTLY DRINK ALCOHOL?   YES  NO   #/DAY   n/a 
BEER (bottles per week)  
WINE (glasses per week)  
LIQUOR (oz. per week)  
 
DO YOU HAVE A HISTORY OF ALCOHOL CONSUMPTION? 
 YES  NO   #YEARS    n/a 
BEER (bottles per week)  
WINE (glasses per week)  




HAVE YOU EVER FELT YOU SHOULD CUT DOWN ON YOUR DRINKING? 
   YES  NO 
HAVE PEOPLE ANNOYED YOU BY CRITICISING YOUR DRINKING? 
   YES  NO 
HAVE YOUR EVERY FELT BAD OR GUILTY ABOUT YOUR DRINKING? 
   YES  NO 
HAVE YOUR EVER HAD A DRINK FIRST THING IN THE MORNING TO STEADY YOUR NERVES 
OR GET RID OF A HANGOVER (EYE-OPENER)? 
  YES  NO 
Health Demographics 
Visit 
Y Y Y Y M M D D 




Assessors Initials:  
 







PLEASE INQUIRE IF THE PARTICIPANT HAS EXPERIENCED ANY OF THESE COMPLICATIONS IN THE 
PAST 3 MONTHS (CHECK ALL THAT APPLY): 
 AUTONOMIC DYSREFLXIA  BLADDER INFECTION  
 PAIN  DEEP VEIN THROMBOSIS  
 PRESSURE SORE  CONSTIPATION 
 SPASTICITY  HETEROTOPIC OSSIFICATION 
 HEMORRHOIDS  BLADDER/KIDNEY STONES  
 INGROWN TOE NAIL   DRUG ADDICTION  
 GI BLEED   NEUROLOGIC DETERIORATION  
 LOW BLOOD PRESSURE   GYNECOLOGICAL PROBLEMS 
 SURGERY  




























Y Y Y Y M M D D 
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Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 















Other Neurological (not 





Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 














Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 












Current Health Status 
Visit 
Y Y Y Y M M D D 





Assessors Initials:  
 











Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 













Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 













Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 













Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 










Current Health Status 
Visit 
Y Y Y Y M M D D 





Assessors Initials:  
 









Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 














Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 













Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 













Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 
If yes,record details: 
 
 







Current Health Status 
Visit 
Y Y Y Y M M D D 
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Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 

















Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 

















Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 

















Start Date : 
/ /
 
D        D         M       M       Y         Y         Y         Y 
Resolution Date : 
/ /  
D        D         M       M       Y         Y         Y         Y 




Ongoing at End 
of Study 
 
Additional pages as required 
Current Health Status 
Visit 
Y Y Y Y M M D D 





Assessors Initials:  
 












CHEMOTHERAPY  YES    NO  YES    NO  
RADIOTHERAPY  YES    NO  YES    NO  
HYPOGONADISM  YES    NO  YES    NO  
THYROID DISEASE  YES    NO  YES    NO  
HYPERTHYROIDISM  YES    NO  YES    NO  
HYPOTHYROIDISM  YES    NO  YES    NO  
INFLAMMATORY BOWEL 
DISEASE 
 YES    NO  YES    NO  
HYPERPARATHYROIDISM  YES    NO  YES    NO  
MYELOMA  YES    NO  YES    NO  
VITAMIN D DEFICIENCY  YES    NO  YES    NO  
LIVER DISEASE  YES    NO  YES    NO  
RENAL FAILURE  YES    NO  YES    NO  
CANCER  YES    NO  YES    NO  
MUSCULOSKELETAL 
PROBLEMS 
(I.E. JOINT PROBLEMS, 
ARTHRITIS, CONTRACTURES) 
 YES    NO  YES    NO  
CARDIOVASCULAR DISEASE 
(OR FAMILY HISTORY) 
 YES    NO  YES    NO  
HIGH BLOOD PRESSURE  YES    NO  YES    NO  
HIGH CHOLESTEROL  YES    NO  YES    NO  
CHEST PAIN / ANGINA  YES    NO  YES    NO  
BRONCHITIS/PNEUMONIA  YES    NO  YES    NO  
  
Visit 
Y Y Y Y M M D D 
/ / Date of Assessment 
Participant ID Diseases/Conditions Affecting Bone Density 
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OTHER DISEASES/CONDITIONS AFFECTING BONE DENSITY 
 
DISEASE/SYSTEM HISTORY OF DISEASE CURRENT DISEASE 
 
OTHER: __________________________ 
 YES    NO  YES    NO 
 
OTHER: __________________________ 
 YES    NO  YES    NO 
 
OTHER: __________________________ 























Y Y Y Y M M D D 
/ / Date of Assessment 
Participant ID Diseases/Conditions Affecting Bone Density 
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1.  (a) Have you had any hospital admissions in the past six months which required an 
overnight stay? (not in emergency)   (1) Yes  (2) No (if no go to question 2) 
 
(b)  For what reason were you admitted to hospital? (check all that apply) 
  (1) Heart Disease    
  (2) Pressure Sores    
  (3) Blood Clot    
  (4) Cancer Treatment specify:      
 (5) Bladder/Kidney Infection 
 (6) Fracture specify:      
 (7) Surgery specify:       
 (8) Medical or Diagnostic Test specify:      
 
2. (a) Have you broken one or more bones in the past six months? 
 (1) Yes -go to (b)  (2) No (If no, thank participant, questionnaire complete) 
 
How many times have you fractured a bone in the last six months?   
 
Complete the following pages (one fracture incident form for each fracture) 
Fracture Ascertainment Questionnaire 
Visit 
Y Y Y Y M M D D 
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Complete the following pages (one fracture incident form for each fracture) 
What was the date of the fracture?    
  / /  
Y   Y  Y   Y   M   M   D   D  
  
 Don’t know 
Which bone was broken? 
 1 Back  (specify if available)____________________    
 2 Hip         1 Left    2 Right 
 3 Ribs/Sternum       1 Left    2 Right 
 4 Forearm/ Wrist       1 Left    2 Right 
 5 Pelvis        
 6 Shoulder (upper arm)      1 Left    2 Right 
 7 Elbow        1 Left    2 Right 
 8 Hand        1 Left    2 Right 
 9 Finger(s)        1 Left    2 Right 
 10 Knee        1 Left    2 Right 
 11 Ankle        1 Left    2 Right 
 12 Foot        1 Left    2 Right 
 13 Upper Leg          1 Left    2 Right 
 14 Lower Leg        1 Left    2 Right 
 15 Toe(s)        1 Left    2 Right 
 16 Other (specify) _________________________     1 Left    2 Right    3 
N/A 
Based on the Interviewers discretion and participant history, was this an incident or fragility 
fracture? 
 1 Incident 











Fracture Incident Form 
Visit 
Y Y Y Y M M D D 
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How did the fracture happen? 
 1  Fell out of bed or off a chair (from sitting position) 
 2  Fell climbing a chair or ladder 
 3  Fell on stairs 
 4  Motor vehicle accident 
 5  Sporting injury 
 6  Slipped or tripped inside the home 
 7  Slipped or tripped outside the home 
 8  Heavy object fell or struck body causing the fracture 
 9 Catching foot or ankle in doorway 
 10 Bone(s) broke with no fall or injury 
 11 Car Transfer  
 12 Other Transfer specify:     
 13 Unknown 
 14 Other (specify) ____________________ 
 
What time of day did the fracture occur?   
 1  Day (8am to 4pm)     2  Evening (4pm to midnight)    3 Night (midnight to 8am) 
 
Were X-rays of the fracture taken?   1 Yes    2 No   3 Don’t know 
If Yes or Don’t know, obtain consent from participant to acquire the X-ray from health 
record  


















Fracture Incident Form 
Visit 
Y Y Y Y M M D D 
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Was the fracture treated by a physician?   1 Yes  2  No (go to question 9) 
 
Where was the fracture first noticed?  (Check all the apply)  
 Hospital  Physician’s office  
                                     (go to question 10) (go to question 11)  
        
 Home Other 
(go to question 12) (go to question 12) 
 
 
Where was the decision made on how to manage your fracture?  (Check all the apply) 
 Hospital  Physician’s office  
                                     (go to question 10) (go to question 11)  
        
 Home Other 



































Fracture Incident Form 
Visit 
Y Y Y Y M M D D 









Assessors Initials:  
 






10. IN HOSPITAL   -    
Date of Admission : 
/ /  
Y  Y   Y  Y     M M     D D  
 
 Don’t know 
 1 Emergency Clinic       2 Fracture Clinic      3 In-Patient →    Length of stay  days 
Hospital Name  _________________________  Don’t know 
Treating Doctor  ________________________  Don’t know 
Treatment received   1 Surgery  2 Cast  3 Other (specify) ________________ 
   ↓ 
      1 Internal and or external fixation (pins, nails, screws) 
      2 Joint replacement 
Where did you go when you left the hospital? 
 1 Home 
 2 Rehabilitation centre           What was the name? ____________ Length of stay:  
days 
 3 Convalescent home  
 4 Other (specify) ___________________ 
11. IN PHYSICIAN’S OFFICE Physician’s name _______________ 
Date of first visit:      Total number of visits:   
/ /  
Y  Y   Y  Y     M M     D D  
 













Fracture Incident Form 
Visit 
Y Y Y Y M M D D 









Assessors Initials:  
 






12. As a consequence of your fracture, were you treated with Physiotherapy?   1 Yes   2 
No      
        # of visits # of weeks 
    in hospital       
    in public rehabilitation centre    
    in private convalescent centre    
    community health centre     
    private clinic      
    at home from a private clinic    
    in senior’s home      
 
As a consequence of your fracture were you visited by an occupational therapist?  
 1 Yes   2 No 
 
If yes, hours per week  # of weeks  
 
If subject has not yet returned home from inpatient stay, go to question 17 
 
As a consequence of your fracture, were you visited at home by a nurse? 
  1 Yes   2 No 
 
If yes, hours per week  # of weeks  
 
As a consequence of your fracture, did you receive help from a homemaker? (meals on 
wheels, housekeeping, personal hygiene)  
 1 Yes   2 No 
 








Fracture Incident Form 
Visit 
Y Y Y Y M M D D 










Assessors Initials:  
 





As a consequence of your fracture, did you receive help from an attendant?  
 1 Yes   2 No 
If yes, hours per week  # of weeks  
As a consequence of your fracture, did you receive help from a family member or friend? 
 1 Yes   2 No↓ 
How many days did you receive help?    days 
Did this person have a paying job?   1  Yes  2  No 
     ↓ 
  How many days off work did this person  
  take as a result of your fracture?                ________ days 
 
Since the fracture, have you temporarily given up any of your usual activities? 
 1 Yes   2 No  If yes, specify:      
 
Since the fracture, have you permanently given up any of your usual activities? 
 1 Yes   2 No  If yes, specify:      
 
Since the fracture do you go out:   1 Less often   2 The same   3 More often 
 
Have you been told that your fracture is osteoporosis related?  
 1 Yes   2 No   3 Don’t know 
 
 
For each fracture incidence, complete the following X-ray Form
Fracture Incident Form 
Visit 
Y Y Y Y M M D D 









Assessors Initials:  
 








Was the consent for medical records abstraction received? 
 
 1 Yes   2 No   
 
X-ray Source:  1 Hospital     2 Physician’s Office     3 Clinic 
 
Any Fracture?  1 Yes   2 No   3 Unknown 
 
 
If yes, complete description of fracture location and type in table below: 
 
Fracture site identified by X-ray 
 
Fracture Location  Side Fracture Type 
 Hip 
 Mid shaft femur 
 Distal Femur 
 Proximal tibia 
 Midshaft tibia 
 Distal tibia 
 Other  
________________ 
 
 Right   Left 
 Right   Left 
 Right   Left 
 Right   Left 
 Right   Left 
 Right   Left 




 Stress/Undisplaced Fracture 
 Compound 
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Y Y Y Y M M D D 










Assessors Initials:  
 














 +  - 
 
.  







 +  - 
 
.  










 +  - 
 
.  











 +  - 
 
.  











 +  - 
 
.  




Body Composition Data from Whole Body Scan 
Fat-free soft tissue 
mass 
Whole Body 
.  kg 
Legs 
.  kg 
Fat mass 
Whole Body 
.  kg 
Legs 
.  kg 
Bone+FFST+Fat 
Whole Body 
.  kg 
Legs 
.  kg 
 





Y Y Y Y M M D D 






Assessors Initials:  
 




pQCT Participant #:  Side:   Right      Left  
Leg Length:  mm Voxel Size:  Name of ROI:    
 
Comments:            
        
4% CT ID:  CONTMODE:  PEELMODE:  
Threshold 1 :  Threshold 2 :  Threshold 3 :  
Total 







.  mm2 
Trabecular 







.  mm2 
Cortical Thickness:  
.  mm 
Mean Hole Size: 
 .  mm 
Max. Hole Size:  
.  mm 
Connectivity Index:  # Nodes:   
 
 




Y Y Y Y M M D D 






Assessors Initials:  
 




38% CT ID:  CONTMODE:  PEELMODE:  
Threshold 1 :  Threshold 2 :  Threshold 3 :  
Total 
BMC / 1mm slice: 
.  mg/mm 
BMD: 
.  mg/cm3 
Area: 
.  mm2 
Cortical &  
Sub-cortical 
BMC / 1mm slice: 
.  mg/mm 
BMD: 
.  mg/cm3 
Area: 
.  mm2 
 Cortical Thickness: .  mm Polar x-sectional MOI: .  mm4 
Connectivity Index:  # Nodes:   
 
66% CT ID:  CONTMODE:  PEELMODE:  
Threshold 1 :  Threshold 2 :  Threshold 3 :  
Total 
BMC / 1mm slice: 
.  mg/mm 
BMD: 
.  mg/cm3 
Area: 
.  mm2 
Cortical &  
Sub-cortical 
BMC / 1mm slice: 
.  mg/mm 
BMD: 
.  mg/cm3 
Area: 
.  mm2 
 Cortical Thickness: .  mm Polar x-sectional MOI: .  mm4 
Connectivity Index:  # Nodes:   




Y Y Y Y M M D D 




















1.Odds ratio and 95% CI analysis with pQCT scans with movement artefacts removed 
2.Poisson regression analysis with pQCT scans with movement artefacts removed  


































Odds ratio and 95% CI analysis with pQCT scans with movement artefacts removed 
 Fractures (Unadjusted) Fractures (Adjusted) 
 OR (95% CI) p-value OR (95% CI) p-value 
aBMD-DF (mg/cm
2




) 0.986 (0.976-0.996) 0.0045* 0.985 (0.971-0.998) 0.0278* 
vBMD (mg/cm
3
) 0.963 (0.936-0.991) 0.0097* 0.968 (0.935-1.003) 0.0731 
HA 1.090 (1.010-1.176) 0.0268* 1.082 (0.999-1.172) 0.0521
 
CTh 0.308 (0.100-0.942) 0.0389* 0.381 (0.118-1.234) 0.1075 
BR 1.452 (0.871-2.418) 0.1525 1.284 (0.755-2.183) 0.3562 
CSMI (cm
4
) 0.138 (0.027-0.709) 0.0177* 0.030 (0.001-0.678) 0.0276* 
PMI (cm
4
) 0.434 (0.197-0.958) 0.0388* 0.346 (0.122-0.983) 0.0463* 
Notes: CI = confidence interval; OR = odds ratio; DF = distal femur; PT = proximal tibia  
†adjusted for correlates of bone strength variables: aBMD at the distal femur and proximal tibia were adjusted for completeness of 
injury and bisphosphonate use; trabecular vBMD was adjusted for duration of injury and completeness of injury; HA, CTh, and BR 
were adjusted for duration of injury; CSMI and PMI were adjusted for gender, completeness of injury, and bisphosphonate use.  
*Statistically significant at alpha=0.05 
 
Poisson regression with pQCT scans with movement artefacts removed 
 Change in log count Upper 95% CI Lower 95% CI p-value 
aBMD-DF (mg/cm
2












) 0.0222 0.0136 0.0309 <0.0001
* 
CTh (mm) -0.6920 -1.1730 -0.2110 0.0048
* 








) -0.5537 -0.9048 -0.2027 0.0020
* 
Notes: CI = confidence interval; DF = distal femur; PT = proximal tibia 

































1 218.7 218.9 0.2 
2 230.9 232.1 1.2 
3  223.6 225.0 1.4 
4 256.9 257.9 1.0 
5 258.1 258.5 0.4 
6 179.9 180.0 0.1 
7 229.2 230.4 1.2 
8 208.8 211.0 2.2 
9 229.5 228.2 1.3 
10 221.5 223.0 1.5 
11 223.7 225.0 1.3 
12 253.1 254.2 1.1 
13 258.5 259.4 0.9 
14 260.2 260.0 -0.2 
15 191.5 193.6 2.1 
 
 
 
 
 
 
 
